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1. Summary 
 
Obesity is linked to a number of comorbidities such as cardiovascular disease, 
musculoskeletal disease, cancer, and type 2 diabetes. Visceral obesity, i.e. adipose 
tissue around the greater omentum and mesentery as well as deep subcutaneous 
layers, is independently and highly correlated to aggravation of several of these 
diseases. This may be due to inherent properties including higher release of free fatty 
acids and higher concentrations of several pro-inflammatory cytokines and 
adipokines which drain into the portal vein promoting the development of (hepatic) 
insulin resistance and liver steatosis. It was shown that in obese and type 2 diabetic 
patients, certain inflammatory cytokines are chronically elevated at low levels. 
Therefore, inflammatory cytokines have been implicated in contributing to or causing 
insulin resistance in organs like liver, skeletal muscle, and white adipose tissue 
(WAT) by directly or indirectly interfering with insulin signalling pathways.  
The aim of this thesis was first to further elucidate the role of WAT 
inflammation in the early setting of high-fat diet-induced insulin resistance as well as 
second, to test the hypothesis that WAT transplantation is capable of interfering with 
auto-regulatory mechanisms of endogenous WAT mass control. 
Regarding the first aim, we were able to demonstrate that a period as short as 
four days of high-fat feeding lead to hepatic insulin resistance, hepatic steatosis, and 
increased mRNA expression of the cytokine tumor necrosis factor α. This effect was 
reversible in animals with an adipocyte-specific deletion of Fas/CD95, a death 
receptor known to contribute to a pro-inflammatory milieu: despite having a similar 
degree of hepatic steatosis, expression of pro-inflammatory cytokines was massively 
reduced in WAT and mice were protected from developing hepatic insulin resistance. 
Regarding the second aim, epididymal WAT was transplanted to the 
mesentery of recipient mice and, thus, drained into the portal vein. Resulting 
increased total WAT mass was not compensated for by a decrease of endogenous 
fat mass as could be expected from published observations. In contrast, total 
endogenous WAT mass was rather increased. We could not allocate this finding to a 
single mechanism; however, indirect evidence suggests a hyperplastic response of 
endogenous WAT, i.e. an increase in adipocyte cell number. 
 1
Together, these studies provide new insights into the role of adipose tissue to 
endogenous fat mass control and to the development of obesity-associated insulin 
resistance.   
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2. Zusammenfassung 
 
Übergewicht und Fettleibigkeit sind mit den häufigsten Zivilisationskrankeiten 
wie kardiovaskuläre Krankheiten, muskuloskeletale Krankheiten, Krebs und Diabetes 
assoziiert. Eine viszerale Fettleibigkeit, d.h. eine Zunahme des weißes Fettgewebes 
im Bereich des Omentums und des Magen-Darm-Traktes, sowie der tiefen 
subkutanen Fettschichten im Bauchbereich, ist unabhängig davon mit einem 
erhöhten Risiko verbunden, eine oder mehrere dieser Krankheiten oder eine 
schwerere Form davon zu entwickeln. Dies ist auf die unterschiedlichen 
Eigenschaften der verschiedenen Fettgewebe zurückzuführen. Das viszerale 
Fettgewebe besitzt eine erhöhte metabolische Rate und schüttet somit mehr freie 
Fettsäuren sowie mehr pro-inflammatorische Zytokine und Adipokine aus, welche 
direkt in die Pfortader drainiert werden und so die Leber einem erhöhtem Stress 
aussetzen. Bei übergewichtigen Menschen und Typ 2 Diabetes Patienten wurde 
zudem eine chronisch leicht erhöhte Menge von Entzündungsfaktoren im Blut 
festgestellt. Daher wird angenommen, dass diese Zytokine an der Entwicklung einer 
Insulinresistenz in Leber, Skelettmuskel oder weißem Fettgewebe beteiligt sind, da 
sie direkt oder indirekt mit der Insulin-Signalkaskade interferieren können. 
Die Ziele der vorliegenden Dissertation waren zum einen den Einfluss der 
Inflammation in weißem Fettgewebe auf die frühzeitige Entwicklung einer 
Insulinresistenz zu untersuchen, sowie zum anderen den Effekt einer viszeralen Fett-
Transplantation auf die Regulierung der endogenen Fettmasse zu analysieren. 
In der ersten Studie konnte aufgezeigt werden, dass eine viertägige 
hochkalorische Fettdiät ausreicht, eine Leberinsulinresistenz zusammen mit einer 
hepatischen Steatose und einer Entzündung im weißen Fettgewebe hervorzurufen. 
Zudem wurde gezeigt, dass eine gezielte Ausschaltung des Fas-Rezeptors (CD95) in 
Adipozyten, welcher in der pro-inflammatorischen Antwort eine Rolle spielt, die 
Entwicklung der Leberinsulinresistenz verhindert, ohne das Ausmaß der 
Lebersteatose zu beeinflussen. Zudem zeigten die Fas-defizienten Mäuse eine 
massive Reduzierung des inflammatorischen Milieus im weißen Fettgewebe. 
In der zweiten Studie wurde epididymales Fettgewebe einer Donor-Maus 
entnommen und anschließend einem Geschwistertier an den Darm transplantiert 
(Akzeptor-Maus). Entgegen der zu erwartenden auto-regulatorisch bedingten 
Abnahme der endogenen Fettmasse als Kompensation des zusätzlich 
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transplantierten Fettgewebes, welche bei Nagern häufig zu beobachten ist, zeigten 
Akzeptormäuse eine Zunahme der endogenen Fettgewebsmasse. Der Mechanismus 
hierfür ist bisher unklar, jedoch deuten indirekte Hinweise darauf hin, dass die 
Zunahme der Fettmasse auf einer hyperplastischen Antwort, d.h. auf einer Zunahme 
der Fettzell-Zahl, und nicht auf einer hypertrophen Reaktion, d.h. auf einer Zunahme 
der Fettzell-Größe, beruht. 
Zusammenfassend unterstreichen diese beiden Studien die Wichtigkeit des 
Fettgewebes in der Entstehung der Obesitas–assoziierten Insulinresistenz und 
weisen auf eine wichtige auto-regulatorische Rolle des Fettgewebes in der Kontrolle 
der Fettmasse hin. 
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3. Abbreviations 
 
ACC   Acetyl-CoA Carboxylase 
AFasKO  Adipocyte-specific Fas knock-out 
AMPK   Adenosine monophosphate-activated protein kinase 
ANCOVA  Analysis of covariance 
AS160  Akt substrate of 160 kDa 
AT   Adipose tissue 
ATGL   Adipose triglyceride lipase 
AUC   Area under the curve 
BAT   Brown adipose tissue 
BM   Body mass 
BMI   Body mass index 
CEBPα  CCAAT/enhancer-binding protein α 
CEBPβ  CCAAT/enhancer-binding protein β 
CEBPδ  CCAAT/enhancer-binding protein δ 
DAG   Diacylglycerol 
DIO   Diet-induced obesity 
EE   Energy expenditure 
ERK 1 / 2  Extracellular signal-regulated kinases 1 and 2 
FA / FFA  Fatty acid / Free fatty acid 
FABP   Fatty acid binding protein 
FATP   Fatty acid transport protein 
FI   Food intake 
G-6-P   Glucose-6-Phosphatase 
GLUT4  Glucose transporter-4 
HFD   High-fat diet 
HMW   High molecular weight 
HSL   Hormone-sensitive lipase 
IKK   Inhibitor of nuclear factor κB kinase 
IL   Interleukin 
IR   Insulin resistance 
IRS   Insulin receptor substrate 
JNK   c-Jun-N-terminal kinase 
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LPL   Lipoprotein lipase 
MCP-1  Monocyte chemotactic protein-1 
mRNA  messenger RNA 
NFκB   Nuclear factor κ B 
PEPCK  Phosphoenolpyruvate carboxykinase 
PKA/C  Protein kinase A /C 
PLIN1   Perilipin 
PPARγ  Peroxisome proliferator-activated receptor γ 
pTx   portal-transplanted mice 
RBP4   Retinol binding protein 4 
SOCS3  Suppressor of cytokine signalling 3 
SREBP  Sterol regulatory element binding protein 
SVF   Stromal vascular fraction 
T1DM   Type 1 diabetes mellitus 
T2DM   Type 2 diabetes mellitus 
TAG /TG  Triacylglycerol / Triglycerides 
TNFα   Tumor necrosis factor α 
TLR   Toll-like receptor 
UCP-1  Uncoupling protein-1 
WAT   White adipose tissue 
scWAT  Subcutaneous WAT 
mWAT  Mesenteric WAT 
rWAT   Retroperitoneal WAT 
iWAT   Inguinal WAT 
eWAT   Epididymal WAT 
WHO   World Health Organisation 
 
4. Introduction 
 
4.1. Obesity 
 
The obesity pandemic has become one of the challenging health problems not 
only in the Western hemisphere but also in Asia and developing countries. It can be 
categorised by the crude measure of body mass index (BMI) which is defined as a 
person’s weight in kilograms divided by the square of his height in metres (1). People 
are considered overweight from a BMI larger than 25 kg/m2 and obese from a BMI 
higher than 30 kg/m2. Overweight and obesity are associated with a number of 
leading causes of global death, including cardiovascular disease, musculoskeletal 
disease, cancer, and diabetes.  
 
According to World Health Organisation (WHO) figures from 2008, the number 
of overweight people with a BMI >25 kg/m2 has doubled since 1980 affecting now 
globally more than 20% of the population, i.e. more than 1.4 billion people (Figure 1). 
Amongst them, more than 1/3 is considered obese. Causes for this increase are 
named to be inactive sedentary lifestyle, i.e. reduced daily physical activity, a greater 
than needed daily caloric intake attributable to the availability of more processed 
energy-dense foods rich in fat and rich in sugar, and a higher degree of urbanization 
pointing towards less active lifestyle and use of common transport systems. This so 
called obesogenic environment together with genetic predisposition may have led to 
the sharp increase over the past 30 years or so (2). The constant increase together 
with the concomitant associated disease development, especially the incident of type 
2 diabetes in even younger population, will be one of the future challenges of modern 
society.  
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Figure 1. Global map of obesity WHO (3) 
 
4.2. Diabetes 
 
Diabetes mellitus can be subdivided in two different types. Type 1 diabetes 
mellitus (T1DM), also known as insulin-dependent or juvenile diabetes, is 
characterised by a malfunction of the pancreas to produce adequate amounts of 
insulin and hence requires constant administration of exogenous insulin. In contrast, 
non-insulin dependent or adult-onset diabetes as type 2 diabetes mellitus (T2DM) is 
described as the inability of the body to make proper use of its insulin, in other words, 
the development of peripheral insulin resistance. In former times mainly affecting the 
elderly population, nowadays more and more younger people suffer from T2DM. As it 
is a silent progressive process, discovery may take up to decades. 
According to the WHO global status report from 2010, diabetes is per se the 
number 5 single cause of global death for non-communicable diseases per year for 
under the age of 70 years. It affects between 9 and 11 % of the general adult 
population aged over 25 years dependent on global region and seems to be 
independent of gross income. If criteria as impaired fasting glycaemia and impaired 
glucose tolerance are included, proportions are higher than above estimates (4). 
However, these conditions are intermediate and do not necessarily lead to T2DM. 
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Approximately 347 million people worldwide suffer from any form of diabetes 
and more intriguingly, WHO estimates of diabetes-caused deaths are to double up to 
2030. This high number almost exceeds even the estimates from a 2004 publication 
on actual and prospective prevalence of diabetes from 2000 to 2030 (5) which, based 
solely on demographic changes, was to more than double from roughly 171 million to 
366 million people. Hence, action needs to be taken to counteract the development 
of excessive increase in adipose tissue mass in people. 
However, not just simply reducing adiposity but rather understanding its 
underlying genetic and environmental influences (see e.g. 6 for recent review) and 
the complex body’s system of regulating its need for foods, the interplay of satiety 
signals, and ultimately increase or decrease of body and fat mass is the major 
challenge of medical research (7), as e.g. dieting and effective weight loss for 
overweight or obese people is ineffective over the long term (e.g. 8). Additionally, 
sole focus on body mass by BMI does not seem to represent the full picture of 
possible disease status and other indices have been used like waist circumference 
and waist-to-hip ratio, which on the one hand are easily measurable but on the other 
hand have some drawbacks as well (see e.g. 9; 10). More recently, several reports 
have again lead to scientific discussions about usefulness of categorising people with 
BMI > 25 kg/m2 as overweight and >30 kg/m2 as obese together with associations of 
increased risk for diseases (e.g. 11; 12-14). The interested reader is referred to a 
recent perspective comment by Ahima and Lazar (15). This may highlight the 
importance of understanding not only proper function of adipose tissue but also its 
distribution sites in the body which show site-specific particularities (16) together with 
proportions of adequate muscle mass simply pointing to the complexity of the system 
as a whole being difficult to categorise with a simple height-by-weight formula. 
 
4.3. Adipose tissue 
 
Adipose tissue (AT) can be largely subdivided histologically and functionally 
into white and brown. White adipose tissue (WAT) consists to great extent of large 
lipid-droplet containing adipocytes, adipocyte precursors, and other cells types 
commonly called stromal-vascular fraction (SVF) which will be further described in 
detail below. In contrast, brown adipose tissue (BAT) and its adipocytes are 
characterised by their colour due to the high density of mitochondria and, compared 
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to WAT, contain multiple lipid droplets. The main function is not to store excessive 
energy but rather to produce heat by non-shivering thermogenesis mediated by 
uncoupling protein-1 (UCP-1) in the respiratory chain. More recently, a third type 
called ‘beige’ or ‘brite’ adipocyte has been identified residing mainly in WAT and 
probably having the same progenitor cell being able, dependent on stimuli, to 
differentiate into either white or beige adipocyte (see also 17). However, beige AT 
and BAT will not be considered to great extent in this introduction and the interested 
reader is referred to recent publications and reviews about its existence and function 
in neonate and adult human beings (e.g. 18; 19-23). 
 
4.4. Development of WAT 
  
The development of adipose tissue starts, dependent on species, at early 
stages of fetal development but seems to be site-specific with time differences for 
different depots as well. For example, in human, pigs and also some rodent but not 
bovine species, subcutaneous WAT (scWAT) apparently seems to develop prior to 
intra-abdominal, e.g. mesenteric WAT (mWAT) or retroperitoneal WAT (rWAT) (24-
31). Remarkable even at that time point is the close association between developing 
adipocytes and vascularisation which distinguishes depots already at such early 
stage (32). It is important to note that in both prenatal and perinatal periods, 
nutritional and hormonal influences seem to imprint subsequent development of 
adipose tissue. For an overview, see Poulous et al. (31). Hence, in utero 
programming of AT as determinant of later (mal-) developments to the disadvantage 
of an unhealthy adipose phenotype has to be considered as well, although data on 
human are sparse and, hence, knowledge stems mostly from large animal studies 
with sheep and pig. 
It should be noted that there is considerable turnover of adipocytes, i.e. 
programmed cell death and adipogenesis at substantial rates of approximately 10% 
per year throughout adult human life span and it was estimated that overall adipocyte 
half-life is around 8.3 years (33). 
Much research has been devoted to understand the 
development/differentiation of pre-adipocytes into adipocytes. A coordinated 
transcriptional cascade is responsible for proper adipocyte differentiation until a 
mature adipocyte reaches its final stage having three primary characteristics 
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including proper lipid storage capacity, insulin sensitivity, and endocrine properties 
(34; 35). At the centre of this network are two master regulators, peroxisome 
proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer-binding protein α 
(CEBPα) which are indispensable for correct adipocyte differentiation and insulin 
sensitivity, respectively (36; 37). Well before these two factors, others like 
CCAAT/enhancer-binding protein β (CEBPβ) and δ (CEBPδ) act in concert at the 
stage of determining the fate of precursor cells towards adipocyte development and 
induce the expression of PPARγ. Ablation of pparγ in embryonic stem cells leads to 
embryonic lethality (38). Further research by Rosen et al. (39) and Koutnikova et al. 
(40) showed that pparγ knockdown lead to severe lipodystrophy. pparγ has two 
isoform, pparγ1 and pparγ2 giving rise to the corresponding PPARγ1 and PPARγ2 
polypeptide, respectively. While PPARγ1 is expressed in many tissues, PPARγ2 is 
restricted to adipose tissue. Interestingly, knockout of adipose-pparg2 can be 
compensated in part by PPARγ1 (41). Similarly, CEBPα knockout in mice comes with 
early lethality due to the inability of these animals to produce glucose as CEBPα is 
indispensable for gluconeogenesis in liver (42). When being knocked out in all 
tissues apart from liver, it was demonstrated that CEBPα is required for formation of 
WAT, but not necessarily BAT (43). Additionally, it was suggested that CEBPα works 
in concert with PPARγ being responsible for proper insulin function in the mature 
adipocyte (43; 44). It was shown in cell models that CEBPβ and CEBPδ are 
expressed earlier than CEBPα in adipogenesis and that they are responsible for 
CEBPα expression (45; 46). These findings were extended to the ability for CEBPβ to 
induce expression of PPARγ2 (47). However, when CEBPβ and CEBPδ were 
knocked out simultaneously, neonatal mice had a defect in producing adipose tissue 
but there was some residual expression of PPARγ and CEBPα suggesting some 
redundancy in the system and an additional role downstream of PPARγ and CEBPα 
since absence of both isoforms prevents terminal adipogenesis (36; 37). A simplified 
model of Whe main factors involved can be seen in Figure 2. It should be noted that 
several other factors like activating protein-1, signal transducers and activators of 
transcription, Krüppel-like factors, sterol regulatory element binding proteins 
(SREBPs), and wingless type MMTV integration site family members (Wnts), to name 
the most prominent ones, are involved as well in positively and/or negatively 
regulating each of these factors at different stages. Besides these transcription 
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factors, adipogenesis can also be hormonally controlled by thyroid hormones, steroid 
hormones, peptide hormones and also glycoproteins (reviewed in 48).  
 
Figure 2. (created with Servier Medical Art www.servier.com). There is no timed order of factors 
positively (+) or negatively (-) regulating adipogenesis. AP-1 = group of activating protein-1, CEBP = 
CCAAT/enhancer-binding protein, STAT = signal transducers and activators of transcription, KLF = 
Krüppel-like factors, PPARγ = peroxisome proliferator-activated receptor γ, SREBP-1 = sterol 
regulatory element binding protein 1, GATA = (A/T)GATA(A/G) binding protein, PREF-1/DLK1 = delta-
like 1 homolog (Drosophila) 
 
4.5. Composition of WAT 
 
Besides mature adipocytes and immature pre-adipocytes, adipose tissue 
comprises of a number of other cell types including endothelial cells, pericytes, 
fibroblasts, several immune cell types like macrophages, eosinophils, natural killer 
cells, B-cells, T-cells, to name just a few, neuronal cells, and others (49-52). 
How the composition thereof may change during development of obesity can 
be exemplified seen in Figure 3 when mice were challenged with a high-fat diet 
(HFD) for 8-12 weeks to promote obesity and their total number of leukocytes of the 
SVF was analysed for its composition. Hence, although changes in composition may 
seem to be of minor extent, underlying physiological output will be altered to great 
extent as will be described later. 
 
 
Figure 3. (from (53)) Treg = regulatory T cells, NKT = natural killer T-cells, MDSC = myeloid derived 
suppressor cells, NK = natural killer cells, B = B-cells, T = T-cells 
 
Physiologically, this was shown to be important for the development and 
maintenance of insulin resistance in HFD animal models. In 2003, two groups could 
demonstrate that infiltration of macrophages was causally linked to insulin resistance 
(IR) as these macrophages secrete large amounts of pro-inflammatory cytokines 
which interfere with normal functioning of WAT (49; 50). Weisberg et al. (49) could 
show that total number of macrophages increased from 5-10% in lean individuals to 
up to 50% of total cells in obese subjects, hence not only qualitative composition as 
shown above but rather quantitative changes towards a pro-inflammatory milieu was 
demonstrated to be causally linked to IR. 
More recently, several papers also proved that either phenotypic changes of 
resident AT macrophages or infiltration of other immune cell types like T-reg cells, 
natural killer T-cells, CD4+ and CD8+ cells may be involved even at earlier time points 
to either induce negative commitment to insulin resistance (IR) and dysfunction or 
contribute in concert with other factors to this deleterious development (52; 54-58). 
Further research is clearly warranted to deduce timely cascade of invasion/attraction 
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of non-resident cells into WAT and their underlying function both in healthy 
expansion of WAT and disease development. 
 
4.6. Site-specific differences of WAT 
 
Adding to the complexity, location of WAT seems to be “a” if not “the” crucial 
point in determining its function, reacting to obesogenic environment, and finally 
being determinant for health status. Simply seen, storage sites can be divided into 
subcutaneous, i.e. between dermis and muscle, and visceral storage, i.e. all depots 
in the intra-abdominal cavity including mWAT, rWAT and omental WAT in human 
beings. Additionally, centrally-located depots (i.e. omental and mesenteric and also 
deep-subcutaneous central WAT) are more closely related to deleterious outcomes 
then peripheral depots (i.e. subcutaneous hip and gluteal-femoral WAT) (59; 60). A 
closer look defines the drainage sites of these depots as well, i.e. if the factors 
released by WAT are directed into systemic circulation (scWAT, rWAT) or into portal 
circulation (mWAT, omental WAT) exposing in a first passage the liver (9; 60-64). In 
rodent models, an additional depot around the gonads – commonly called 
perigonadal WAT for both sexes and/or epididymal WAT, eWAT, for male mice – 
located inside the intra-abdominal cavity but draining into the systemic circulation has 
to be considered as it is one of the most reacting sites during an obesogenic 
challenge (62-65) and is frequently used for WAT analysis. 
The site of adipose is of importance as different depots possess different 
properties in storing excess energy, reacting to diverse stimuli and releasing factors 
called “adipokines” into circulation. As mentioned in the beginning, not merely total 
adipose tissue mass but rather its distribution may be more closely linked to 
deleterious outcomes, foremost associated to the metabolic syndrome.  
Adipocyte size in humans, for example, is larger in mesenteric and perirenal 
depots and smallest in omental depots whereas scWAT shows intermediate size (31; 
60). Additionally, scWAT is more heterogeneous and contains both unilocular 
adipocytes together with smaller multilocular adipocytes whereas visceral fat is more 
uniform (63). This may have implications as adipocyte turnover may occur at different 
rates in these depots and the capacity to recruit more adipocytes (hyperplasia) is 
associated with healthy expansion of adipose tissue in general (60; 63; 66). 
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In rodents, however, eWAT has larger adipocytes than scWAT or mWAT and 
responds more hypertrophic under obesogenic HFD challenge (e.g. 67). 
Nevertheless, mWAT has much higher lipolytic response to e.g. catecholamines, i.e. 
the capacity to break down and release free fatty acids (FFA) into circulation in 
situation when energy is needed (68). This poses an extra threat to excessive large 
visceral depots as FFAs released in great excess have deleterious effects on other 
organs (69). Conversely, the anti-lipolytic effect of insulin is lower in mWAT versus 
scWAT (60; 70; 71). In rodents, the situation of intra-abdominal WAT is also site-
specific. For example Wueest et al. (67; 72) could show that isolated eWAT, mWAT, 
and scWAT have different basal lipolytic rates, different inhibition rate under insulin 
challenge and that these inherent properties are differentially altered under HFD 
challenge. 
Importantly, adipocytes retain their characteristics when isolated and cultured 
(60; 73) and it seems that even when autologously transplanted, keep their 
properties and original function intact. However, this was not uniformly observed (65; 
74). In these settings, transplanted donor tissue and proper re-vascularisation as well 
as drainage site may be a decisive factor for different outcomes (75; 76).  
More recent reports provide therefore support for intrinsic distinctions in 
adipocyte precursor cells from several depots in rodents, a divergent capacity to 
differentiate and substantial differences in gene expression influencing adipogenesis 
and capacity of releasing different factors (77; 78). Lately, large-scale gene 
expression analysis and secretome analysis of various human and rodent adipose 
tissue depots has provided conclusive insights into the differences between depots, 
their alterations in obesity and under HFD, and the complexities when comparing 
“adipose tissue” with each other (79-87). 
 
4.7. Adipose tissue as secretory organ 
 
Besides its function as a cushion and storage site for energy when available in 
excess and its release when in demand, WAT’s role in releasing autocrine, paracrine 
and endocrine factors has become evident during the past 20 years. 
The main function of adipocytes is to take up fatty acids (FA), store them 
properly as triacylglycerols (TAGs), or commonly named triglycerides (TGs), and 
release them in situations of energy need. For that purpose, TGs are transported in 
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the bloodstream via lipoproteins (chylomicrons, very-low density lipoproteins) and are 
unloaded in the presence of the endothelial-bound lipoprotein lipase (LPL) of the 
target cell (88). Subsequently, the released FAs are taken up by membrane 
transporters like fatty acid translocase (FAT/CD36), fatty acid transport proteins 
(FATPs), plasma-membrane bound FATP (FATPpm), and long-chain fatty acid Acyl-
coenzyme A synthetase (ACSL), (89-91). They then are intracellularly shuttled by 
fatty acid binding proteins (FABPs) to the correct site in the cytoplasm and re-
esterified to TAG (92). The other way round, several lipases are necessary for 
breaking down TAG to FAs so that they can be made of use for energy production or 
serve as signalOing events. Foremost, upon lipolytic stimuli and activation of protein 
kinase A (PKA), perilipin (PLIN1), a lipid-coating and protecting protein, is 
phosphorylated which promotes the release of comparative gene identification-58 
(CGI-58), which subsequently recruits hormone sensitive lipase (HSL) to the 
corresponding lipid droplet. CGI-58 binds with adipose tissue triglyceride lipase 
(ATGL) and both translocate to the droplet where ATGL catalyzes the first step from 
TAG to diacylglycerol (DAG) releasing one FA. PKA also phosphorylates HSL which 
then attaches to the lipid droplet surface and catalyzes the second step from DAG to 
monoacylglycerol (MAG) yielding another FA. Finally, monoglycerol lipase is 
responsible for the last hydrolyzation step yielding glycerol and another FA (93-99). 
Figures 4 and 5 illustrate current views on above described pathways. 
 
 
 
Figure 4. (from (88)) MG = Monoacylglycerol, DG = Diacylglycerol, TG = Triacylglycerol, FA = Fatty 
acid, PLC = Phospholipase C, DAGL = Diacylgylcerol Lipase, LPL = Lipoprotein Lipase, GP1HBP1 = 
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glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1, Gly = Glycerol, CM = 
Chylomicron, VLDL = very low density lipoprotein 
 
 
 
Figure 5. (Reprinted from (100) with permission from Elsevier) FA = Fatty acid, ACS1 = 
AcylCoASynthetase 1, FATP1 = Fatty acid transport protein 1, FABP = Fatty acid binding protein (c = 
cytosolic, pm = plasma membrane-bound), CoA = Coenzyme A, VLC-FA = very long chain fatty acid 
 
Importantly, both the intermediate products of TAG catabolism and the released free 
FA exert numerous signalling functions and e.g. intervene directly with other kinases, 
as well as regulate a number of transcription factors besides their role as energetic 
source (93; 101; 102). 
 
4.8. Adipokines 
 
 During the past two decades, a second and equally important function of WAT 
has been described, namely the production and release of autocrine, paracrine, and 
endocrine acting molecules named adipokines and also cytokines from adipocytes 
per se or from cells of the SVF compartment of WAT. The origin of the most 
important and best characterised ones and their function in metabolism and related 
to WAT changes will be described briefly in the section below. In general, this has 
made WAT to one of the key organs in regulating both its own metabolism and 
influencing other organs like skeletal muscle, liver, brain, pancreas, and surrounding 
vasculature in diverse processes as lipid and carbohydrate metabolism, state of 
inflammation, blood pressure, energy expenditure and feeding status (31; 103). 
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Leptin has been one of the first adipokines to be discovered. It is the product 
of the ob gene (104), mainly produced in adipocytes and in low levels in several other 
organs (105; 106). Leptin is released into the bloodstream, increases with weight 
gain, decreases during weight loss and fasting and is a direct signal of fat store. 
Large adipocytes release more leptin than small ones, subcutaneous WAT more than 
omental one (107). Leptin, together with insulin, acts centrally to directly inhibit 
appetite (108), and low levels of leptin inhibit action of anabolic state, i.e. growth 
hormone, thyroid hormone, and sexual hormone release and lowers thermogenesis 
(109-111). Its production is regulated by several factors including insulin, 
inflammatory cytokines, glucocorticoids as well as also by meal ingestion or fasting 
(112; 113).  
Leptin acts through the leptin receptor which is the product of the db gene, 
(114) being highly expressed in certain brain regions, especially the hypothalamus, 
and, hence, central action after crossing the blood-brain-barrier makes leptin to act 
as a direct satiety signal and fat mass scale. Additionally, leptin acts peripherally on 
liver, skeletal muscle and adipose tissue itself again as these tissues express one or 
several isoforms of the leptin receptor (115; 116). Direct actions of leptin in the brain 
involve inhibition of appetite, stimulating processes like thermogenesis, fatty acid 
oxidation, and reducing body weight (106; 117). In the periphery, leptin e.g. induces 
lipolysis in adipocytes and skeletal muscle as well as increases lipid oxidation in the 
liver (118-121). Additionally, mounting evidence suggests a direct or indirect role of 
leptin in maintaining glucose homeostasis, especially in peripheral insulin sensitivity 
(108). This made leptin an ideal candidate for therapeutic use in obesity. However, in 
obesity, high levels of circulating leptin are observed even when corrected for 
adipose tissue mass which translates to a relative leptin resistance or insensitivity in 
obesity state (122). This resistance is immanent both centrally and in the periphery 
(123; 124).  
 
Adiponectin has also been discovered in the mid-1990s (125) as direct 
secretory product of adipocytes, and, conversely to leptin, circulating adiponectin was 
shown to be decreased with increasing fat mass in diverse populations and diet-
induced obesity (DIO) models (126-128). Moreover, it is inversely related to risk 
development of obesity, IR, T2DM, and cardiovascular disease (129; 130).  
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Adiponectin acts via adiponectin receptors 1 and 2 (ADIPOR1 and 2, 
respectively) which are ubiquitously expressed and may exert some redundancy 
when knocked-out selectively (131). Although adiponectin is fairly stable in circulation, 
its plasma half-life is only 45-75 min which suggests rapid clearance by other organs 
of which the liver is the main one (132).  
Adiponectin secretion in humans is higher from omental than scWAT depots 
and exists in several multimeric complexes generally termed low-molecular weight, 
LMW, or high-molecular weight, HMW, adiponectin of which only the latter shows 
bioactivity on receptors (133). It should be noted that the decrease of circulating 
adiponectin seen in T2DM is mostly seen in the HMW form and focusing on this form 
even strengthens above mentioned correlations (134). It was shown to promote 
pancreatic beta cell function, i.e. probably increase insulin secretion (135), and 
survival by activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and 
also Akt (135; 136). Additionally, adiponectin exerts cardioprotective function 
probably via reducing ceramide levels (137). Adiponectin’s action on skeletal muscle 
improving peripheral insulin sensitivity via increasing glucose uptake seems to be 
mediated by adenosine monophosphate-activated protein kinase (AMPK) activation 
(138; 139), however doubts remain as to whether the HMW multimeric form, which is 
the predominant plasma circulating adiponectin, exerts the same role as most early 
studies demonstrating an effect in muscle used globular adiponectin (summarised in 
140). On the contrary, adiponectin suppresses hepatic glucose output via priming 
hepatocytes to the effects of insulin. It reduces gene expression of 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G-6-P), 
two key regulators of gluconeogenesis (141). This effect on liver seems to be both 
AMPK-dependent and independent. Concerning adipose tissue, adiponectin seems 
to exert autocrine and paracrine effects. Overexpressing adiponectin leads to healthy 
expansion of WAT, i.e. an increase in adipocyte number (hyperplasia) rather than 
hypertrophy of existing adipocytes in a genetic mouse model of obesity together with 
a lower degree of inflammation (142; 143). Furthermore, adiponectin has profound 
anti-inflammatory properties as it suppresses growth and proliferation of macrophage 
progenitors (144) and reduces release of pro-inflammatory cytokines when co-
incubated with human macrophages (144) whereas release of anti-inflammatory 
interleukin-10 (IL-10) is increased (145; 146). Importantly, these anti-inflammatory 
 19
properties are not limited to WAT but rather seem to be globally as several 
macrophages residing at different organs are positively influenced. 
 
4.9. Further adipokines 
 
 Besides these two well-characterised adipokines, several others have been 
found and are still to be discovered. Some of them are exclusively expressed in 
adipocytes, some also in other cell types but predominantly in adipocytes. Amongst 
them are those without hormonal function like apolipoprotein A which is a component 
of TG-rich lipoproteins, transforming growth factor beta which regulates preadipocyte 
proliferation and differentiation, and also LPL whose role is described above. Other 
factors exerting local and more systemic functions include Adipsin which stimulates 
TG storage; Apelin having an effect on cardiovascular function and fluid retention; 
acylation-stimulation protein being involved in TG synthesis; omentin which may be 
involved in insulin action; serum retinol binding protein 4 (RBP4) which increases 
with obesity and promotes IR (147). Similarly to RBP4 is resistin, at least in rodents, 
whereas its role in humans is less clear as there is some controversy about its 
origination, preadipocytes, adipocytes (148) or mononuclear blood cells (149; 150); 
and visfatin which was initially supposed to be an insulin mimetic being higher 
expressed in visceral vs. scWAT, however, more recent data demonstrated that it is 
an extracellular form of nicotinamide phosphorybosyl transferase being essential in 
NAD biosynthesis (151; see 152 for an overview). More recently, adipocyte fatty acid 
binding protein (AFABP or FABP4), an intracellular fatty acid transporter, has been 
implicated in IR and dyslipidemia as it was shown to be elevated in development of 
T2DM and the metabolic syndrome (153; 154). An overview about other adipokines 
can be found in Catalan et al. (155) or Maury and Brichard (156). 
 
4.10. Inflammation and inflammatory cytokines in WAT 
 
As indicated above, WAT contributes to inflammatory state in health and 
disease state. Adipocytes, but mostly other cell types from the SVF secrete both pro-
inflammatory cytokines like tumour necrosis factor alpha (TNFα) and interleukin-6 (IL-
6) or interleukin-1 (IL-1) as well as anti-inflammatory cytokines like IL-10 and 
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chemokines like monocyte chemotactic protein-1 (MCP-1) which modulate local and 
systemic processes. Obesity is associated with chronic low grade inflammation, i.e. 
elevated circulating pro-inflammatory cytokines, which to a large extent stem from 
WAT (157; 158). In this regard, macrophages, either resident or infiltrating, play an 
important role. They show roughly two phenotypes: classically pro-inflammatory M1 
macrophages and alternatively-activated anti-inflammatory M2 macrophages (159). 
However, distinction may somewhat differ in a broad continuum. Nevertheless, 
obesity is associated with a huge increase in total macrophage number (indicated 
above) and additionally, a switch from M2 to M1 macrophages (159). M1 
macrophages are usually recruited to sites of lesion or damage and secrete pro-
inflammatory cytokines like IL-6 and TNFα, whereas M2 macrophages release for 
example IL-10. These factors have direct, local effects on adipocytes, as well as 
peripheral effects by interfering with insulin signalling pathways in liver and skeletal 
muscle. The complex interplay between residing and or invading cell types during 
developmental changes of WAT in obesity was recently extensively reviewed (53; 
160-163) and is summarized in descriptive ways in figure 6 which displays the 
immune cell populations in WAT and figure 7 which shows interactions between 
these cell types and macrophage polarization in development of obesity. 
Two of the most prominent pro-inflammatory cytokines released by WAT and 
being somehow involved in the stages from obesity to IR will be further described 
below. 
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Figure 6. (from (53)) For abbreviations, see text. 
 
 
Figure 7. (from (161)) IL = interleukin, IgG = Immunglobulin G. For other abbreviations, see text. 
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TNFα can be synthesized by adipocytes but the main contribution in obese 
state stems from M1 polarized macrophages (49). It was the first cytokine derived 
from WAT which provided a link between obesity, inflammation, and development of 
T2DM (164). It is released into circulation and can exert both local paracrine effects 
as well as endocrine effects on diverse target cells and tissues (e.g. 165). Direct 
effects on adipocytes are reported to be inhibition of lipogenesis, an increase in 
lipolysis, and a decrease in glucose transporter-4 (GLUT4), CEBPα, PPARγ, Perilipin, 
fat-specific protein 27 and adiponectin expression amongst others (166; 167). TNFα 
expression and release is increased in obesity (168) and can directly impair insulin 
signalling in WAT, muscle, and liver (169-172) whereas deletion of TNFα or its 
receptors protects animals under obesogenic HFD from deterioration of insulin 
sensitivity and glucose tolerance (164; 173). Concerning impaired insulin signalling, 
TNFα acts on the insulin receptor substrate (IRS) phosphorylation sites through c-
Jun-N-terminal kinase (JNK) (174) and inhibitor of nuclear factor κB (NFκB) kinase 
(IKK) and through activating suppressor of cytokine signalling 3 (SOCS3) (175). 
Thereby, it can furthermore enhance other pro-inflammatory cytokines like IL-6 or IL-
1 (176). Additionally, it inhibits fatty acid oxidation through protein phosphatase 2C 
and this further leads to an accumulation of DAGs which may further impair IRS 
signalling (177). Thus, it seemed promising to use neutralizing antibodies to reduce 
circulating TNFα. Whereas this strategy is successful in rodents (e.g. 54; 164), 
results in humans are not as clear (178; 179) and warrant further investigation in 
larger settings. 
 
 Being discovered in the mid-1980s (180), IL-6 gained widespread 
considerable and controversial interest through its diverse properties in a short- and 
long-term setting (181-186; summarised in 187) as it is associated with a number of 
diseases like rheumatoid arthritis, Crohn’s disease or some form of cancers (188). IL-
6 is expressed and secreted by a large number of cell types including adipocytes, 
preadipocytes, macrophages, and endothelial cells amongst others (e.g. 60; 189) 
and released into circulation whereas WAT is supposed to contribute around 1/3 
(190). Like many other cytokines and adipokines, site-specific differences in 
expression and secretion exist (9) with omental WAT releasing more IL-6 than 
scWAT. Its expression and release into circulation in obesity and T2DM is elevated 
similar to TNFα (191; 192) and it may directly impair insulin signalling either via 
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downregulating IRS (193) or upregulating SOCS3 in several insulin-targeting cell 
types (194-196). As it has lipolytic function as well (197), it may further promote 
release of FFA into circulation which, as mentioned before, may also interfere with 
insulin signalling (191). Furthermore, it suppresses adiponectin production (198) and 
also LPL activity (199). IL-6 acts either via IL-6 receptor or the pleiotropic 
glycoprotein 130 (gp130) receptor on its target cell (200; 201), which adds to the 
complexity of this cytokine. Knocking IL-6 out on a whole-body level leads apparently 
to a complex phenotype with in part opposing results (202; 203). However, a more 
recent study confirmed that these animals develop mature onset obesity when fed a 
normal chow diet and develop IR, liver steatosis and inflammation suggesting some 
necessary roles beyond its promoting pro-inflammatory role (204) and hence 
targeting its receptors may be more promising (188). However, a certain amount of 
IL-6 signalling also seems to be indispensable as for example IL-6R alpha deficiency 
specifically in hepatocytes leads to insulin resistance and glucose intolerance (205). 
 
4.11. Insulin Signalling and Resistance 
 
Insulin is an anabolic hormone produced in the islets of Langerhans in the 
pancreas and is released upon a rise in blood glucose with its main function to keep 
blood glucose concentration in a narrow range. For that purpose, it stimulates 
glucose uptake into target tissues like skeletal muscle and WAT. In liver and muscle, 
it promotes glucose storage into glycogen and inhibits glycogen breakdown. In 
addition, insulin suppresses hepatic gluconeogenesis which maintains glucose 
concentration during fasting. Only a minor portion of the circulating glucose is taken 
up by WAT pointing to an important function of skeletal muscle for glucose clearance. 
The glucose taken up by WAT is mainly used as backbone for TAG formation by 
providing intracellular substrate for glycerol-3-phosphate (206). Furthermore, insulin 
promotes uptake of circulating TAG and FAs via LPL activity and FATP1 
translocation to the plasma membrane and synthesis of FAs via acetyl-CoA 
carboxylase (ACC) in adipocytes as well as intracellular TAG formation. It 
suppresses FA release into circulation contributing to its postprandial clearance via 
reducing cyclic adenosine monophosphate (cAMP) levels and PKA activity, as well 
as indirectly inhibiting ATGL messenger RNA (mRNA) levels and upregulating fat-
specific protein 27 (207). 
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 Insulin acts via binding to the insulin receptor, a tyrosine kinase, which leads 
to initiation of a signalling cascade via phosphorylation of IRS. Subsequently, further 
downstream signalling cascades like for example in skeletal muscle, liver, and WAT 
the phosphatidyl inositol 3-kinase (PI-3-K) - phosphatidyl inositol-dependent kinase 
(PDK) - serine/threonine protein kinase Akt - atypical protein kinase C isoforms λ and 
ζ are activated, leading in the case of skeletal muscle and WAT via Akt substrate of 
160 kDa (AS160) and Rab guanosine triphosphatase (Rab-GTPase) to GLUT4 
translocation and glucose uptake (e.g. 208). 
Failure of insulin to promote its proper function is considered as insulin 
resistance of the affected tissue/cell. Proper insulin signalling may be impaired at any 
step, via phosphorylation of inhibitory sites, de-phosphorylation of activating sites, 
post-translational modification of enzymes, transcriptional repression of genes, or 
other events. FA, lipid intermediates like DAG or ceramides, inflammatory cytokines, 
adipokines and even high glucose levels may interfere with insulin signalling. 
Thereby, several pathways converge at different points. For example, TNFα, via its 
receptor, activates JNK1 which in turn is able to phosphorylate serine sites at IRS. 
DAG, either via lipolytic pathway or TAG formation is able to activate PKC θ, which 
acts on IRS as well. Some fatty acids have been shown to bind to toll-like receptors 
(TLRs) of which TLR4 activates IKK which impacts ceramide synthesis which 
subsequently may act on Akt phosphorylation by protein phosphatase 2A or PKC ζ. 
In this sense it seems that not TG per se, but rather lipid intermediates are in part 
responsible for or contributing to IR (207; 208). 
Hence a complex interplay between signals derived from WAT in the form of 
cytokines and adipokines activating or reinforcing immune response as well as 
diverse lipid intermediates derived from altered lipolytic or lipogenetic function of 
adipocytes and hepatocytes play a role in developing, manifesting and aggravating 
the state of tissue IR. However, the exact time-dependent signalling events and the 
contribution of both inflammation and lipids solely or in concert remain incompletely 
understood.  
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4.12. Hypotheses and aims 
 
Given the information above, the purpose of this thesis was to shed further 
light on the function of WAT in two different research settings in rodent models: First, 
to better understand its role and inter-organ crosstalk in a short-term overfeeding 
setting and the subsequent development of insulin resistance. And second, to use a 
WAT transplant-model (75) to understand the possible role of endogenous graft 
properties and site-specific effects in auto-regulating WAT mass. 
For the first study, 12 week old male C57BL/6J mice were overfed for four 
days with a caloric dense HFD or a control chow diet. Additionally, animals with 
adipocyte-specific deletion of Fas/CD95, a known factor to influence inflammation, 
were used in this setting to further specify the role of WAT inflammation in the early 
development of IR. We hypothesized that even at such early stage, inflammation 
occurring in WAT plays a role in the development of hepatic insulin resistance and 
that adipocyte-specific Fas knock-out (AFasKO) animals would be protected from 
that development which was shown in a long-term setting (209). Further details and 
results are summarised under “project 1”. 
For the second study, preliminary unpublished data suggested differential 
regulation of fat mass. Therefore, we used our previously implemented 
transplantation model (75) to search for factors released by WAT or liver or via inter-
organ crosstalk which may regulate endogenous WAT mass after site-specific 
transplantation of exogenous donor WAT. For that purpose, eWAT from littermate 
donors was transplanted to the intestine (portal-transplanted animals, pTx) of 
C57BL/6J mice and, subsequently, the impact on body and WAT mass as well as on 
metabolic markers was studied. We hypothesized that WAT transplantation site 
would increase WAT total mass. This may be due to (a) factor(s) released by the 
transplant and/or neural innervation which either directly provide feedback to central 
regions or via portal drainage feed back from the liver to the brain and hence would 
influence food intake, energy expenditure, or main regulators of WAT expansion. 
Further details and preliminary results are summarised under “project 2”. 
 
5. Results 
 
Project 1: 
 
5.1 Adipose tissue inflammation contributes to short-term high-fat diet-induced 
hepatic insulin resistance. 
Michael Wiedemann, Stephan Wueest, Flurin Item, Eugen J. Schoenle, Daniel 
Konrad 
Am J Physiol Endocrinol Metab 305: E388–E395, 2013. 
 
5.2 Short-term HFD does not alter lipolytic function of adipocytes. 
Michael Wiedemann, Stephan Wueest, Alexandra Grob, Flurin Item, Eugen J. 
Schoenle, Daniel Konrad 
Adipocyte 3:2, 1–6; April/May/June 2014 
 
Project 2: 
 
5.3 Portal vein-drained adipose tissue transplants increase endogenous adipose 
tissue mass 
Michael Wiedemann, Stephan Wueest, Eugen J. Schoenle, Daniel Konrad 
Unpublished  
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5.1. Adipose tissue inflammation contributes to short-term high-fat 
diet-induced hepatic insulin resistance 
 
Authors: Michael Wiedemann, Stephan Wueest, Flurin Item, Eugen J. Schoenle, 
Daniel Konrad 
Journal: Am J Physiol Endocrinol Metab 305: E388–E395, 2013. 
DOI:  10.1152/ajpendo.00179.2013. 
PMID:  23736545 
Contribution: Design, performance, analysis and interpretation of experiments Fig.  
1A, E, Fig. 2B, C, Fig. 3A, B, Fig. 4A-C, Fig. 5A, E, Fig. 6B, C; editing 
and revising the manuscript. 
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Wiedemann MS, Wueest S, Item F, Schoenle EJ, Konrad D.
Adipose tissue inflammation contributes to short-term high-fat
diet-induced hepatic insulin resistance. Am J Physiol Endocrinol
Metab 305: E388 –E395, 2013. First published June 4, 2013;
doi:10.1152/ajpendo.00179.2013.—High-fat feeding for 3–4 days
impairs glucose tolerance and hepatic insulin sensitivity. However, it
remains unclear whether the evolving hepatic insulin resistance is due
to acute lipid overload or the result of induced adipose tissue inflam-
mation and consequent dysfunctional adipose tissue-liver cross-talk.
In the present study, feeding C57Bl6/J mice a fat-enriched diet
[high-fat diet (HFD)] for 4 days induced glucose intolerance, hepatic
insulin resistance (as assessed by hyperinsulinemic euglycemic clamp
studies), and hepatic steatosis as well as adipose tissue inflammation
(i.e., TNF expression) compared with standard chow-fed mice.
Adipocyte-specific depletion of the antiapoptotic/anti-inflammatory
factor Fas (CD95) attenuated adipose tissue inflammation and im-
proved glucose tolerance as well as hepatic insulin sensitivity without
altering the level of hepatic steatosis induced by HFD. In summary,
our results identify adipose tissue inflammation and resulting dysfunc-
tional adipose tissue-liver cross-talk as an early event in the develop-
ment of HFD-induced hepatic insulin resistance.
adipose tissue-liver cross-talk; lipotoxicity; diabetes mellitus
IN OBESITY, ADIPOSE TISSUE EXPANSION is accompanied by local
infiltration of different types of inflammatory cells (3). The
emerging cross-talk between infiltrating inflammatory cells and
local cells, such as adipocytes, results in altered adipokine as
well as increased proinflammatory cytokine production and
secretion. Consequently, insulin resistance evolves both locally
as well as systemically, e.g., in the liver, due to the evolving
dysfunctional interorgan crosstalk (6, 8). Consistently imping-
ing on adipose tissue inflammation improves obesity-associ-
ated insulin resistance (19, 20, 22, 25). Thus, adipose tissue
inflammation may trigger hepatic insulin resistance potentially
via the release of cytokines and/or lipids into the circulation.
In susceptible mouse strains, obesity and associated insulin
resistance may be induced by a fat-enriched diet. It was
demonstrated recently that a short period of high-fat diet
(HFD), i.e., for 3–4 days, is sufficient to induce hepatic
steatosis, hepatic insulin resistance, and adipose tissue inflam-
mation (7, 13). However, it remains unclear whether hepatic
insulin resistance (and hepatic steatosis) induced by a short
bout of HFD is the result of acute lipid overload or whether it
is at least partly mediated by adipose tissue inflammation, as it
was demonstrated for long-term HFD feeding.
To assess a potential contribution of adipose tissue inflam-
mation to short-term HFD-induced insulin resistance, we per-
formed experiments in wild-type and adipocyte-specific Fas-
knockout mice. We provide evidence that a short challenge of
HFD triggers adipose tissue inflammation and hepatic insulin
resistance in wild-type mice. Moreover, interfering with adi-
pose tissue inflammation via adipocyte-specific Fas depletion
preserved hepatic insulin sensitivity, suggesting that adipose
tissue inflammation contributes to HFD-induced hepatic insu-
lin resistance as early as 4 days after initiation of HFD.
MATERIALS AND METHODS
Animals. C57BL/6J mice were obtained from The Jackson Labo-
ratory. Adipocyte-specific Fas-knockout mice (Fasadipo) were gener-
ated as follows; mice with exon IX of Fas flanked with LoxP sites [a
gift of Dr. A. Chervonsky, University of Chicago, and produced as
described elsewhere (23)] were crossed with mice expressing Cre
recombinase controlled by the Fabp4 promoter [B6.Cg-Tg(Fabp4-
cre)1Rev/J; purchased from The Jackson Laboratory]. All mice were
genotyped as described (25). Experiments presented in Figs. 1–3 were
performed in Fasf/f mice. In all experiments, including Fasadipo, the latter
were compared with Fasf/f control littermates. In total, 94 mice were used
for this study.
Twelve-week-old male mice were fed ad libitum with standard
rodent diet (chow) or HFD (D12331; Research Diets, New Bruns-
wick, NJ) for 4 days. HFD consisted of 58% of calories derived from
fat, 25.5% from carbohydrate, and 16.5% from protein. Mice were
fasted for 5 h prior to euthanization. All protocols conformed to the
Swiss animal protection laws and were approved by the Cantonal
Veterinary Office in Zurich, Switzerland.
Intraperitoneal glucose tolerance test. Mice were injected intra-
peritoneally with 2 g/kg body wt glucose after overnight fasting, as
described previously (11). Blood glucose concentration was measured
with a Glucometer (Accu-Check Aviva; Roche Diagnostics, Rotkreuz,
Switzerland) with blood from tail-tip bleedings.
Hyperinsulinemic euglycemic clamp studies. Hyperinsulinemic eu-
glycemic clamp studies with an insulin infusion rate of 18 mU·kg1·min1
were performed as described (17). Clamps were performed in freely
moving mice. Glucose infusion rate was calculated once glucose
infusion reached a more or less constant rate with blood glucose levels
at 5 mmol/l (80–90 min after the start of insulin infusion). Thereafter,
blood glucose was kept constant at 5 mmol/l for 15–20 min, and
glucose infusion rate was calculated. The glucose disposal rate was
calculated by dividing the rate of [3-3H]glucose infusion by the
plasma [3-3H]glucose-specific activity (4, 9). Endogenous glucose
production during the clamp was calculated by subtracting the glucose
infusion rate from the glucose disposal rate (4, 9). Insulin-stimulated
glucose disposal rate was calculated by subtracting basal endogenous
Address for reprint requests and other correspondence: D. Konrad, Univ.
Children’s Hospital, Div. of Endocrinology and Diabetology, Steinwiesstrasse 75,
CH-8032 Zurich (e-mail: daniel.konrad@kispi.uzh.ch).
Am J Physiol Endocrinol Metab 305: E388–E395, 2013.
First published June 4, 2013; doi:10.1152/ajpendo.00179.2013.
0193-1849/13 Copyright © 2013 the American Physiological Society http://www.ajpendo.orgE388
glucose production (equal to basal glucose disposal rate) from glucose
disposal rate during the clamp (18).
Determination of plasma insulin, free fatty acid, and triglyceride
levels. Blood was sampled in mice fasted for 5 h. Plasma free fatty
acid and triglyceride levels were determined as described elsewhere
(25). Plasma insulin levels were measured using an ELISA kit as
described previously (11).
Western blotting. For assessing insulin-stimulated Akt phosphoryla-
tion in liver, insulin (1 U/kg) was injected intraperitoneally in mice fasted
for 5 h. Liver samples were harvested 15 min after insulin injection,
snap-frozen in liquid nitrogen and stored at80°C until homogenization.
Liver samples or isolated adipocytes for Fas determination were homog-
enized as described previously (24). Protein concentration was deter-
mined using BCA assay (Pierce, Rockford, IL), and equivalent amounts
of protein (50–75 g) were resolved by LDS-PAGE (4–12% gel,
NuPAGE; Invitrogen). Proteins were electrotransferred onto nitrocellu-
lose membranes (0.2 m; Bio-Rad, Reinach, Switzerland), and equal
loading was confirmed by Ponceau S staining. The following primary
antibodies were used: anti-Fas (Upstate, Lake Placid, NY), anti-actin
(Millipore, Zug, Switzerland), and anti-phospho-Akt (Ser473; Cell Sig-
naling Technology, Danvers, MA). Membranes were exposed in an
Image Reader and analyzed with Image Analyzer (FujiFilm, Dielsdorf,
Switzerland). Arbitrary values obtained with Image Analyzer were nor-
malized to an average of 1 in the control group.
RNA extraction and quantitative RT-PCR. Total RNA was extracted
from epididymal or mesenteric adipose tissue using the RNeasy Lipid
Tissue Mini Kit (Qiagen, Basel, Switzerland), and concentration was
determined spectrophotometrically (Nanodrop 1000; Nanodrop Technol-
ogies, Boston, MA). The integrity of each mesenteric fat RNA sample
was examined by Agilent Lab-on-a-chip technology using the RNA 6000
Nano LabChip kit and a bioanalyzer 2100 (both Agilent Technologies,
Basel, Switzerland). An RNA integrity number 8.0 was considered as
acceptable for further processing; 0.75–1 g of RNA was reverse tran-
scribed with Superscript III Reverse Transcriptase (Invitrogen, Basel,
Switzerland) using a random hexamer primer (Invitrogen). Taqman
(Applied Biosystems, Rotkreuz, Switzerland) was used for real-time PCR
amplification. The following PCR primers (Applied Biosystems) were
used: TNF Mm00443258_m1, IL-6 Mm00446190_m1, cd11b
Mm00434455_m1, cd11c Mm00498698_m1, F4/80 Mm00802529_
m1, MCP-1 Mm00441242_m1, IL-10 Mm00439614_m1, CD36
Mm00432403_m1, CD8 Mm00438116_m1, IFN Mm01168134_m1,
MIP-1Mm99999057_m1, and Ela3b Mm00840378_m1. Relative gene
expression was obtained after normalization to 18sRNA (Applied Bio-
systems), using the formula 2Cp (16).
Total liver lipid determination. Liver tissue (10 –30 mg) was
homogenized in PBS, and lipids were extracted in a chloroform-
methanol (2:1) mixture. Total liver lipids were determined by a
sulfophosphovanillin reaction, as described previously (10).
Histology. Liver tissues were fixed in 4% buffered formalin and
embedded in paraffin. Sections were cut and stained with hematoxylin
and eosin.
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Fig. 1. Four days of high-fat diet (HFD) in-
duces hepatic insulin resistance. A: intraperi-
toneal glucose tolerance test (2 g/kg body wt)
was performed in chow-fed () and HFD-fed
mice (Œ). Results are the means of 5 animals/
group. B–D: hyperinsulinemic euglycemic
clamp studies with glucose infusion rate, insu-
lin-stimulated glucose disposal rate (IS-GDR),
and basal as well as insulin-inhibited endoge-
nous glucose production (EGP) were con-
ducted in chow-fed (black bars) and HFD-fed
mice (open bars). Results are means of 3
(chow-fed) or 9 (HFD-fed) animals. E: insulin
(1 U/kg) was injected intraperitoneally (ip) in
mice fasted for 5 h. Liver samples were har-
vested 15 min later, and phosphorylation of Akt
at Ser473 was determined by Western blotting. A
representative blot is shown at the top; n 3–4.
*P  0.05 (Student’s t-test). All error bars rep-
resent SE. *P  0.05, **P  0.01, and ***P 
0.001 (Student’s t-test).
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Data analysis. Statistical analyses were performed using Student’s
t-test. P values 0.05 were considered significant. All error bars
represent SE.
RESULTS
Four days of HFD induces hepatic insulin resistance in
C57BL6/J mice. To determine a potential impact of short-term
HFD on glucose metabolism, intraperitoneal glucose tolerance
test was performed in 12-wk-old mice receiving either a 58
cal% HFD for 4 days or a standard chow diet. As depicted in
Fig. 1A, glucose tolerance was deteriorated significantly in
HFD-fed littermates [area under the curve (AUC) in HFD-fed
mice 1,761 	 78 mmol·l1·min vs. AUC in chow-fed mice
1,433 	 50 mmol·l1·min; P  0.01]. Of note is that body
weight was similar between both groups (26.4 	 1.0 g in
HFD-fed mice vs. 25.6 	 1.2 g in chow-fed animals; P 
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0.55). To assess insulin sensitivity, hyperinsulinemic euglyce-
mic clamp studies were performed. Glucose infusion rate was
decreased significantly in HFD-fed mice, reflecting reduced
total body insulin sensitivity (Fig. 1B). Whereas insulin-stim-
ulated glucose disposal rate was not significantly diminished
(Fig. 1C), insulin-mediated inhibition of endogenous (mainly
reflecting hepatic) glucose production was reduced in HFD-fed
mice (Fig. 1D), suggesting that a short bout of HFD impacts
mainly on hepatic insulin sensitivity. Similarly, insulin-stimu-
lated Akt phosphorylation was reduced significantly in HFD
compared with chow-fed mice (Fig. 1E). Of note is that total
Akt protein levels were not different between the groups (data
not shown).
Four days of HFD induces liver steatosis. Hepatic steatosis
is strongly associated with insulin resistance; however, it is
presently unclear whether insulin resistance causes hepatic
steatosis or whether the increase in triglycerides or lipid me-
tabolites causes the development of hepatic insulin resistance.
As depicted in Fig. 2, A and B, 4 days of HFD was sufficient
to increase hepatic lipid accumulation, as assessed by histo-
logical examinations and biochemical determination of total
liver lipid content. In contrast, short-term high-fat feeding had
no major impact on liver inflammation, as determined by
mRNA expression of inflammatory as well as macrophage
markers (Fig. 2C). Of note is that liver TNF expression was
reduced upon HFD, which is in accordance with previously
published data reporting a trend toward decreased TNF liver
transcription after short bouts of high-fat feeding (13). Re-
duced CD8 mRNA expression may suggest lower T cell
infiltration in livers of HFD-fed mice.
Four days of HFD increases adipose tissue TNF expression.
Previously, 3–4 days of HFD was reported to induce adipose
tissue inflammation (7, 12, 13). Therefore, we determined
mRNA expression of proinflammatory cytokines and macro-
phage markers in epididymal as well as mesenteric adipose
tissue. As shown in Fig. 3, A and B, TNF expression was
increased significantly in mesenteric fat pads and trendwise in
epididymal fat pads of HFD-fed compared with chow-fed
mice. Of note is that harvesting of mesenteric adipose tissue is
not that simple and is often contaminated by pancreatic tissue
(2). To make sure that a pure fraction of mesenteric adipose
tissue was analyzed, expression of Ela3b was determined. All
samples included expressed Ela3b at a very low level confirm-
ing pure fraction of mesenteric adipose tissue. Therefore, as
reported previously (13), a short bout of HFD was sufficient to
induce TNF expression in adipose tissue.
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HFD-fed adipocyte-specific Fas-knockout mice express de-
creased levels of proinflammatory cytokines in white adipose
tissue. In the present study, we aimed to determine whether
adipose tissue inflammation contributes to HFD-induced he-
patic insulin resistance as early as 4 days after initiation of
high-fat feeding. Previously, we found that adipocyte-specific
Fas-knockout mice (Fasadipo) were protected from long-term
HFD-induced insulin resistance (25). Importantly, adipose
tissue inflammation was reduced in Fasadipo mice and was as-
sociated with improved hepatic insulin sensitivity. Therefore, if
adipose tissue inflammation contributes to short-term HFD-
induced hepatic insulin resistance, Fasadipo mice may be a
good model to study the presence of such cross-talk. As
depicted in Fig. 4A, 4 days of HFD increased Fas protein
content significantly in isolated adipocytes of wild-type
mice. Moreover, expression of proinflammatory cytokines
and macrophage markers was reduced significantly in both
epididymal as well as mesenteric pat pads of Fasadipo mice
challenged by a short bout of HFD compared with control
littermates (Fig. 4, B and C), suggesting that Fas depletion
diminished adipose tissue inflammation. Further phenotypic
characteristics of HFD-fed Fasf/f and Fasadipo mice are
described in Table 1.
Adipocyte-specific Fas-knockout mice are protected from
short-term HFD-induced hepatic insulin resistance. We next
assessed glucose metabolism in HFD-fed adipocyte-specific Fas-
knockout and control mice. As depicted (Fig. 5A), glucose toler-
ance was improved significantly in HFD-fed Fasadipo mice com-
pared with control mice (AUC in Fasadipo mice 1,564 	 66
mmol·l1·min vs. AUC in Fasf/f mice 1,717 	 42 mmol·l1·min;
P  0.05). In hyperinsulinemic euglycemic clamp studies, glu-
cose infusion rate was not different between Fasf/f and Fasadipo
mice (Fig. 5B). In contrast to insulin-stimulated glucose dis-
posal rate, which was not different between the two groups
Table 1. Phenotypic characteristics of HFD-fed Fasf/f
and Fasadipo mice
Fasf/f Fasadipo
Body weight, g 27.6 	 0.5 28.5 	 0.4
Epididymal fat mass, mg 288.6 	 33.6 304.4 	 21.3
Mesenteric fat mass, mg 248.4 	 21.3 269.4 	 23.2
Blood glucose, mmol/l 8.8 	 0.2 9.3 	 0.3
Insulin, pmol/l 0.85 	 0.30 1.06 	 0.22
FFA, mmol/l 0.58 	 0.10 0.65 	 0.11
TG, mg/dl 78.1 	 10.4 104.3 	 18.5
Results are means 	 SE of 6–25 mice fasted for 5 h. FFA, free fatty acids;
TG, triglycerides. Differences between both groups were statistically not
significant.
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Fig. 5. Adipocyte-specific Fas-knockout mice
are protected from HFD-induced hepatic insu-
lin resistance. A: intraperitoneal glucose toler-
ance test (2 g/kg body wt) was performed in
HFD-fed Fasf/f (Œ) and Fasadipo mice (gray
circles). Results are the means of 11 (Fasf/f) or 8
animals (Fasadipo). B–D: hyperinsulinemic
euglycemic clamp studies with glucose infu-
sion rate, IS-GDR, and basal as well as insu-
lin-inhibited EGP were conducted in HFD-fed
Fasf/f (open bars) and Fasadipo mice (gray
bars). Results are the means of 9 (Fasf/f) or 7
animals (Fasadipo). E: insulin (1 U/kg) was
injected ip in mice fasted for 5 h. Liver sam-
ples were harvested 15 min later, and phos-
phorylation of Akt at Ser473 was determined
by Western blotting. Western blot is shown at
the top; n  5/group. All error bars represent
SE. *P  0.05; **P  0.01 (Student’s t-test).
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(Fig. 5C), insulin-mediated inhibition of hepatic glucose pro-
duction was almost completely preserved in Fasadipo mice,
whereas it was clearly blunted in Fas-expressing littermates
(Fig. 5D). Similarly, insulin-stimulated Akt phosphorylation
was sustained in livers of Fasadipo mice compared with control
mice (Fig. 5E). Of note, total Akt protein levels were not
different between the groups (data not shown). Thus, adi-
pocyte-specific Fas-knockout mice are protected from HFD-
induced hepatic insulin resistance.
Adipocyte-specific Fas depletion has no impact on liver lipid
accumulation. In contrast to improved hepatic insulin sensitiv-
ity, total liver lipid content was not different between HFD-fed
adipocyte-specific Fas-knockout and control mice (Fig. 6,
A and B). Similarly, expression of several inflammation mark-
ers was similar between both groups (Fig. 6C). Thus, Fas
depletion in adipocytes protects mice from developing short-
term HFD-induced adipose tissue inflammation and hepatic
insulin resistance but not hepatic steatosis.
DISCUSSION
The present study suggests that adipose tissue inflamma-
tion contributes to short-term HFD-induced hepatic insulin
resistance. Such a notion is based on the following findings:
1) 4 days of HFD induces adipose tissue TNF expression;
2) glucose intolerance as well as hepatic insulin resistance
develops 4 days after initiation of HFD; and 3) Fas depletion
specifically in adipocytes reduces both HFD-induced adi-
pose tissue inflammation as well as hepatic insulin resis-
tance.
Several lines point toward a role of adipose tissue inflam-
mation in the development of hepatic insulin resistance in
obesity. It is thought that increased production and release
of proinflammatory cytokines from visceral, i.e., omental
and mesenteric adipose tissue into the portal vein, may
contribute to the development of hepatic insulin resistance (6). A
role for such dysfunctional fat-liver cross-talk in the pathogen-
esis of obesity-associated hepatic insulin resistance is sup-
ported by the fact that impinging on adipose tissue inflamma-
tion protects against HFD-induced insulin resistance and ste-
atosis (15, 20, 25). Our findings presented here suggest that
adipose tissue inflammation occurs early on in the course of
HFD-induced metabolic alterations and contributes to hepatic
insulin resistance. Such results seem to be in contrast to
previous findings claiming that short-term HFD-induced insu-
lin resistance is independent of inflammation (13). Although
this study demonstrates induction of adipose tissue inflamma-
tion as manifested by an increase in macrophage infiltration of
adipose tissue as well as by increased expression of proinflam-
matory cytokines (mainly TNF), it fails to show a beneficial
effect of macrophage and lymphocyte depletion as well as of
hematopoietic cell-specific Jun NH2-terminal kinase (JNK)-
deficiency on short-term HFD-induced insulin resistance in
mice (13). In contrast, we find herein a favorable effect of
adipocyte-specific Fas deficiency on both adipose tissue in-
flammation and hepatic insulin sensitivity. Of note, differences
in TNF expression were stronger in mesenteric compared
with epididymal adipose tissue, supporting the “portal theory.”
The latter proposes that the liver is exposed directly to increas-
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ing amounts of free fatty acids and/or proinflammatory factors
released from visceral fat into the portal vein, promoting the
development of hepatic insulin resistance (6). Our findings
presented here may suggest that short-term HFD-increased
TNF expression in adipose tissue induces hepatic insulin
resistance. In support of such a notion, TNF was shown
recently to induce insulin resistance in hepatocytes in culture
(5). Moreover, it was reported that inhibition of TNF by the
monoclonal antibody infliximab improves HFD-induced he-
patic insulin resistance in rats (1).
There is a strong association between hepatic steatosis
and insulin resistance, although it is still debated whether
insulin resistance is the cause of hepatic steatosis or whether
the increase in triglycerides (or of lipid metabolites such as
ceramides, diacylglycerol, and acyl-CoAs) causes the devel-
opment of hepatic and/or systemic insulin resistance (14). In
this regard, our observation that Fasadipo mice were pro-
tected from hepatic insulin resistance but not hepatic ste-
atosis is intriguing and indicates that the latter may be the
result of an acute lipid overload rather than a dysfunctional
adipose tissue-liver cross-talk at an early stage of HFD.
Moreover, it may suggest that short-term HFD-induced
hepatic steatosis develops independently of concomitant
hepatic insulin resistance. Supporting this notion, it was
reported previously that 3 days of HFD induced hepatic
insulin resistance and steatosis as well as hepatic inflamma-
tion and Kupffer cell activation. Interestingly, depletion of
the latter improved hepatic insulin sensitivity, whereas it did
not affect hepatic steatosis (12). Conversely, Samuel et al.
(21) reported in rats that treatment with 2,4-dinitrophenol
normalized short-term HFD-induced hepatic steatosis,
whereas it improved only partly the ability of insulin to
suppress endogenous glucose production. Of note is that
Fasadipo mice depicted both improved hepatic insulin sen-
sitivity as well as reduced total liver lipid content after 6 wk
of HFD (25), suggesting that, later in the course of HFD-
induced obesity, adipose tissue inflammation and its result-
ing dysfunctional adipose tissue-liver cross-talk may impact
on both hepatic insulin sensitivity as well as hepatic steato-
sis.
In conclusion, our results identify adipose tissue inflamma-
tion and consecutive dysfunctional adipose tissue-liver cross-
talk as an early event in the development of HFD-induced
deterioration of hepatic insulin sensitivity.
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Brief report
Three to four days of HFD suffice to induce hepatic insu-
lin resistance, hepatic steatosis, and adipose tissue inflammation 
in susceptible mouse strains.1-4 However it remains debatable 
whether the acute dietary lipid overload, increased FFAs mobi-
lized from endogenous fat depots, or inflammatory cytokines—
all known to have causal roles in above mentioned processes 
per se—are responsible for the observed metabolic changes. We 
recently provided evidence that adipose tissue inflammation and 
an early dysfunctional crosstalk between adipose tissue and liver 
participates in the development of hepatic insulin resistance.5 
To this end, adipocyte-specific Fas/CD95-deficient (FasΔadipo) 
or backcrossed control (Fasf/f) mice on a C57BL/6J background 
were fed either standard chow or HFD (12% or 58% of calories 
derived from fat) for 4 d. Besides its well-known role in the reg-
ulation of apoptosis, Fas/CD95 can also induce non-apoptotic 
pathways.6 In particular, Fas activation mediates the secretion of 
pro-inflammatory cytokines7,8 and its adipocyte-specific expres-
sion may contribute to obesity-induced adipose tissue inflam-
mation, hepatic insulin resistance as well as hepatic steatosis.9 
Feeding mice a HFD for four days induced Fas protein level 
in isolated adipocytes, mesenteric adipose tissue inflammation 
(i.e., TNFα expression), hepatic steatosis, and hepatic insulin 
resistance as assessed by hyperinsulinemic–euglycemic clamp.5 
Of note, adipocyte-specific Fas depletion relieved adipose tis-
sue inflammation and hepatic insulin resistance without altering 
the degree of hepatic steatosis. Accordingly, it was recently dem-
onstrated that TNFα release from WAT explants was increased 
after three days of HFD feeding and that TNFα neutralization 
prevented the development of hepatic insulin resistance.1 These 
data suggest that adipose tissue inflammation and resulting dys-
functional adipose tissue-liver crosstalk, at least partly mediated 
via TNFα, is an early event in the development of HFD-induced 
insulin resistance. Moreover, the observation that improved 
hepatic insulin sensitivity in adipocyte-specific Fas knockout 
mice was not associated with decreased hepatic steatosis5 would 
suggest that hepatic fat accumulation after a short bout of high fat 
feeding plays no major role in the development of hepatic insu-
lin resistance and that adipose tissue inflammation and hepatic 
steatosis are two distinct processes in the development of hepatic 
insulin resistance.
Previously, we observed that eight weeks of HFD increased 
basal lipolysis and blunted insulin’s ability to inhibit FFA release 
from isolated epididymal adipocytes.10,11 Herein, we aimed to 
investigate whether four days of HFD were sufficient to affect 
lipolysis. We first determined body weight and adipose tissue 
mass of mice fed either a chow or a HFD for 4 d. Contrary to 
other reports investigating the effect of short-term HFD,1,2,4 we 
did not observe any impact of 4 d of HFD on body weight gain 
(chow-fed mice 0.2 ± 0.2 g, n = 22; HFD-fed mice 0.6 ± 0.2 g, n 
= 12; P = 0.16) or adipose tissue mass (Fig. 1A). Similarly, fast-
ing glucose (chow-fed mice 8.1 ± 0.4 mmol/l, n = 14; HFD-fed 
mice 8.3 ± 0.3 mmol/l, n = 11; P = 0.70) and fasting insulin levels 
(chow-fed mice 0.67 ± 0.20 ng/ml, n = 6; HFD-fed mice 0.85 
± 0.27 ng/ml, n = 6; P = 0.61) were not different between the 
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A short bout of high fat diet (HfD) impairs glucose tolerance and hepatic insulin sensitivity. We recently identified 
adipose tissue inflammation and resulting dysfunctional adipose tissue–liver cross-talk as an early event in the devel-
opment of HfD-induced hepatic insulin resistance. in particular, reducing white adipose tissue (WAt) inflammation by 
adipocyte-specific depletion of fas/CD95 protected mice from developing hepatic insulin resistance but not hepatic 
steatosis. Herein, we expanded our previous work and determined the impact of four days of HfD on lipolytic activity 
of isolated adipocytes. Compared with chow-fed mice, the degree of basal and isoproterenol-stimulated free fatty acid 
(ffA) and glycerol release was similar in HfD-fed animals. Moreover, insulin’s ability to suppress lipolysis remained intact 
suggesting retained insulin sensitivity. Despite unaltered lipolysis, circulating ffA concentrations were greatly increased 
in non-fasted HfD-fed mice. in conclusion, a short-term HfD challenge does not affect lipolytic function of adipocytes. 
the observed increase of circulating ffA levels in randomly fed animals may rather be the result of increased dietary fat 
supply.
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groups. Moreover, neither distribution of adipocyte according to 
their cell size (Fig. 1B) nor average adipocyte diameter (Fig. 1C) 
was different between chow- and HFD-fed mice. Importantly, 
release of lactate dehydrogenase (LDH) was similar suggesting 
comparable viability of isolated adipocytes from chow-fed and 
HFD-fed animals (Fig. 1D).
Lipolytic activity of epididymal adipocytes isolated from fed 
mice was assessed next. As depicted in Figure 2A and B, neither 
basal nor isoproterenol-stimulated lipolysis did differ between 
chow-fed and HFD-fed animals. In addition, the fold increase in 
isoproterenol-induced FFA release (chow 6.9 ± 1.8-fold vs. HFD 
8.0 ± 2.9-fold; P = 0.75) and glycerol release (chow 4.9 ± 0.8-
fold vs. HFD 4.2 ± 0.5-fold; P = 0.43) was similar, suggesting 
alike sensitivity to isoproterenol. Comparable basal and isopro-
terenol stimulated FFA and glycerol release suggested a similar 
degree of re-esterification. Indeed, calculations according to 
Rosenstock et al.12 revealed similar degrees of re-esterification for 
both basal (chow 33.7 ± 12.5% vs. HFD 51.5 ± 9.8%; P = 0.30) 
and isoproterenol-stimulated (chow 17.3 ± 4.9% vs. HFD 24.3 ± 
6.2%; P = 0.41) lipolysis in both groups. Moreover, the ability of 
insulin to inhibit lipolysis (Fig. 2C) and to stimulate Akt phos-
phorylation (Fig. 2D) remained intact in adipocytes of HFD-
fed mice suggesting no deterioration of insulin sensitivity in the 
latter. Even though lipolytic activity was similar between chow- 
and HFD-fed animals, circulating FFA levels were significantly 
increased in the latter in the fed state (Fig. 2E) whereas glyc-
erol and triglyceride levels were not different (Fig. 2F and G). 
Similarly, increased FFA levels were previously reported for short-
term HFD-fed non-fasted rats.13,14 However, after five hours of 
fasting FFA concentrations were similar between chow- and 
HFD-fed mice (Fig. 2H). Likewise, FFA levels were found to 
be no longer different between chow- and short-term HFD-fed 
animals after various periods of fasting,13,15-17 i.e., circulating FFA 
levels did increase in chow-fed animals during fasting to match 
FFA concentrations observed in HFD-fed animals. Of note, sim-
ilar levels of phospho-HSL and phospho-perilipin were found in 
epididymal WAT after 5 h of fasting (Fig. 2I) suggesting similar 
lipolytic activity of WAT in both groups.
The fact that lipolysis was not affected by a short bout of 
HFD would suggest that increased circulating FFA levels in the 
fed state of short-term HFD-fed mice are rather the result of 
increased dietary fat supply. Interestingly, a short period of HFD 
sufficed to induce hepatic steatosis3,5,13 whereas it did not result 
in any significant increase in skeletal muscle and adipose fat 
accumulation as reported herein for adipose tissue and described 
previously for both skeletal muscle and/or adipose tissue.13,18 It 
is conceivable that the development of hepatic fat accumulation 
results from increased FFA flux into hepatocytes due to a dietary-
induced rise in circulating FFA levels in the postprandial state. 
In this regard, a similar fat composition between the liver and 
Figure 1. Similar fat pad weights and adipocyte size in chow- and short-term HfD-fed mice. (A) fat pad weight of different adipose depots was deter-
mined in chow- (black bars) and short-term HfD-fed (open bars) mice. results are the means ± SeM of 11–14 mice. epi, epididymal; mes, mesenteric; 
retro, retroperitoneal; ing, inguinal. Adipocyte cell size distribution of isolated epididymal adipocytes (B), mean adipocyte diameter (C), and viability of 
isolated adipocytes determined via a lactate-dehydrogenase assay (D) are depicted for chow-fed (black bars) and HfD-fed (open bars) non-fasted mice. 
results are the means ± SeM of 4 independent experiments.
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Figure 2A–G (For H–K, see page 4). Similar lipolytic activity but increased non-fasted circulating ffA levels in short-term HfD-fed mice. Basal, isopro-
terenol-stimulated (A and B), and insulin-inhibited (C) ffA or glycerol release from adipocytes isolated from epididymal WAt of chow-fed (black bars) 
and HfD-fed (open bars) mice are depicted. results are the means ± SeM of 4 independent experiments in non-fasted mice. (D) insulin (1 U/kg) was 
injected i.p. in randomly fed mice. epididymal WAt was harvested 15 min later and phosphorylation of Akt at Ser473 was determined and normalized 
to actin (n = 4). representative blots are shown. ffA (E), glycerol (F), as well as triglycerides (G) levels were determined in systemic blood plasma of non-
fasted mice, n = 4. (H) ffA levels were determined in systemic blood plasma in mice fasted for 5 h, n = 6. (I) phospho-HSL (Ser660) and phospho-perilipin 
(Ser522) protein levels were determined in epididymal WAt harvested from chow-fed (black bars) and HfD-fed (open bars) mice fasted for 5 h (n = 6) and 
normalized to actin. representative blots are shown. fAtp1 (J) and GLUt4 (K) content was analyzed in epididymal WAt harvested from randomly fed 
mice (n = 4). representative blots are shown. All error bars represent SeM *P < 0.05 and ***P < 0.001 (Student t test), #P < 0.05 (isoproterenol vs. basal; 
Mann–Whitney U test).
diet, both having an abundance of 18:2 fatty acid, was previ-
ously demonstrated.13 The evolving hepatic insulin resistance 
may then serve as early adaptation mechanism to protect the liver 
from further fat accumulation. As previously demonstrated we 
did not observe increased mRNA expression of macrophage or 
inflammatory markers in livers of mice fed a fat-enriched diet for 
four days. Moreover, as mentioned above, a reduction of adipose 
tissue inflammation had no impact on short-term HFD-induced 
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hepatic steatosis but improved hepatic insulin sensitivity. Thus, 
such result would suggest that short-term HFD-induced hepatic 
insulin resistance is not the result of hepatic inflammation or 
hepatic fat accumulation. Of note, insulin sensitivity of skeletal 
muscle and adipose tissue was retained after four days of HFD 
as shown herein and as was previously reported.1,3,5,13 The antici-
pated increase in circulating insulin levels due to hepatic insulin 
resistance19 may enhance insulin-stimulated glucose uptake into 
adipose tissue and, thus, evolving fat accumulation.
Potentially, reduced fatty acid uptake by adipocytes may lead 
to increased circulating FFA levels (due to reduced FFA flux into 
adipocytes) and hence, to reduced re-esterification. However, as 
depicted in Figure 2A, FFA levels in the incubation media of 
adipocytes of chow- and HFD-fed mice were similar, as was the 
Figure 2G–K. for figure legend, see page 3.
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degree of re-esterification. In addition, protein abundance of the 
long-chain fatty acid transporters FATP1 (ACSVL5) was even 
increased in adipose tissue of HFD-fed mice (Fig. 2J). Hence, 
such data would suggest that there is no impaired capacity of FFA 
uptake into adipocytes of HFD-fed mice. Likewise, basal and 
insulin-stimulated glucose uptake does not appear to be affected 
by short-term HFD as indicated by similar GLUT1 (not shown) 
and increased GLUT4 (Fig. 2K) content as well as preserved 
insulin-stimulated Akt phosphorylation (Fig. 2D).
In conclusion, short-term HFD does not affect lipolytic activ-
ity of isolated adipocytes. The observed increase of circulating 
FFA levels in randomly fed animals after short-term high fat 
feeding may rather be the result of increased dietary fat supply.
Materials and Methods
Animals
C57BL/6J mice were originally obtained from The Jackson 
Laboratory and then bred in our own facility. At the age of 12 wk 
animals were fed ad libitum with standard rodent diet (chow) 
or HFD (D12331, Research Diets) for 4 d. HFD consisted of 
58% of calories derived from fat, 25.5% from carbohydrates, and 
16.5% from protein. For additional experiments, mice were not 
fasted prior to sacrifice to be able to analyze adipocytes in a fed 
(baseline) state as there seems to be a rapid change e.g., in cir-
culating FFAs with prolonged periods of fasting.13 All protocols 
conformed to the Swiss animal protection laws and were approved 
by the Cantonal Veterinary Office in Zurich, Switzerland.
Determination of plasma glucose and insulin levels
Blood was sampled in mice fasted for 5 h. Blood glucose con-
centration was measured with a Glucometer (Accu-Check Aviva, 
Roche Diagnostics) with blood from tail-tip bleedings. Plasma 
insulin levels were measured using an ELISA kit as described 
previously.20
Viability assessment and cell size determination
Adipocytes were isolated and viability was determined with 
an LDH assay as described previously.21 Aliquots of isolated adi-
pocytes were used to determine mean cell diameters. Cell size 
was analyzed by a Multisizer™ 3 Coulter Counter® as follows. 
Two hundred microliters of isolated adipocytes were incubated 
in 2 ml of 2% osmium tetroxide in a collidine solution at 37 
°C for 48 h. Cells were strained with a 250 μm nylon mesh 
and second with a 40 μm mesh and in-between fraction was 
counted.
Lipolysis assays
Lipolysis was assessed in isolated adipocytes as indicated. 
Isolated adipocytes were incubated in the absence or pres-
ence of 100 nM insulin or 1 μM isoproterenol (Sigma) for one 
hour.21 FFA levels were measured using the ACS-ACOD-MEHA 
method from Wako Chemicals GmbH. Triglyceride and glycerol 
levels were determined using a colorimetric assay, as described.9
Western blotting
Samples were homogenized as described previously.21 Protein 
concentration was determined using BCA assay (Pierce), and 
equivalent amounts of protein (30–40 μg) were resolved by LDS-
PAGE (4–12% gel, NuPAGE; Invitrogen). Proteins were electro-
transferred onto nitrocellulose membranes (0.2 μm; Bio-Rad) or 
PVDF membranes (0.45 μm; Roche Diagnostics GmbH), and 
equal loading was confirmed by Ponceau S staining. The follow-
ing primary antibodies were used: anti-actin was purchased from 
Millipore, anti-phospho-HSL (Ser660) as well as anti-phospho-
Akt (Ser473) and total Akt from Cell Signaling Technology, 
anti-FATP1 from Santa Cruz Biotechnology, and anti-phospho-
Perilipin (Ser522) from Vala Sciences. Primary antibodies against 
GLUT1 and GLUT4 were a kind gift from Dr Amira Klip, The 
Hospital for Sick Children, Toronto, Canada. Membranes were 
exposed in an Image Reader and analyzed with Image Analyzer 
(FujiFilm). Arbitrary values obtained with Image Analyzer were 
normalized to an average of 1 in the control chow-fed group.
Data analysis
Statistical analyses were performed using the Student t test or 
Mann–Whitney U test where appropriate. P values < 0.05 were 
considered significant. All error bars represent SEM.
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Abstract 
 
White adipose tissue (WAT) is capable of auto-regulating its own mass as was 
demonstrated by its removal, its addition through transplantation or its removal and 
autologous replacement. Herein, we tested the hypothesis that increasing portal-
drained WAT mass in normal chow-fed C57BL/6 mice leads to dys-regulation of total 
body fat mass. Four weeks after transplantation, endogenous fat pad mass was 
increased by approximately 20% in mice receiving a portal-drained fat transplant. 
Importantly, the impact on endogenous fat mass seemed to be dependent on the 
amount of fat transplanted since small transplants had no effect on endogenous fat 
pad regulation. Food intake, energy expenditure or activity parameters were not 
different between sham-operated and transplanted mice. The observed increase in 
endogenous fat mass can currently not be clearly attributed to either a hypertrophic 
or hyperplastic response, or both, and requests further mechanistic evaluation. 
Indirect evidence from former experiments, however, suggests rather a hyperplastic 
than a hypertrophic response of endogenous WAT depots in transplanted mice. 
Collectively, our findings may suggest a disturbed regulation of endogenous fat mass 
in mice receiving a portal vein-drained fat transplant. 
 
Key words: adipose tissue, WAT, transplantation, tissue cross-talk 
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Introduction 
 
White adipose tissue (WAT) was initially regarded solely as storage organ 
accumulating excess energy in form of triglycerides and releasing mainly free fatty 
acids when fuel is needed. During the past 20 years, however, it became evident that 
adipose tissue has endocrine functions mediated by the secretion of different 
adipokines, cytokines and fat-derived metabolites, which may act locally, i.e. in an 
autocrine/paracrine manner, or affect more distant organs such as the liver (1-3), and 
actively contribute to the regulation of energy balance (4).  
Food intake, energy expenditure and fat mass are tightly regulated, reflecting 
powerful neuro-endocrine feedback circuits that mediate the crosstalk between the 
brain (where feeding and energy expenditure are controlled) and adipose tissue 
(where excess energy in stored). The first hormone to exemplify this system was the 
adipokine leptin, which is released in response to an increase in fat mass to inhibit 
food intake and to augment energy expenditure (5). Interestingly, obese patients 
develop (central) leptin resistance, potentially maintaining obesity by insufficient 
leptin-mediated inhibition of food intake and/or insufficient stimulation of energy 
expenditure (6). In addition to leptin, several other hormones and cytokines released 
from fat tissue, pancreas and the gut (incretins) transmit peripheral signals to the 
central nervous system in order to regulate food intake and energy expenditure, a 
system that when properly regulated acts to maintain body weight. Conversely, 
alterations in this tight regulation may result in obesity. Empirically, it is well known 
that some individuals are more prone to become obese whereas others are protected. 
It is conceivable that such susceptibility/resistance to obesity is linked to differences 
in these neuro-endocrine feedback loops. 
There is increasing evidence that adipose tissue may not only be the main 
effector of such feedback mechanisms (by storing excessive energy), but may 
actively contribute to the control of food intake and energy expenditure. For example, 
removal of fat tissue on one site leads to compensatory augmentation of fat mass in 
other depots resulting in maintained overall fat mass (7). Moreover, Rooks et al. (8) 
demonstrated that subcutaneous transplantation of donor eWAT would lead to a 
reduction in endogenous WAT mass of the transplanted animals without major 
alterations in other parameters. In addition, we previously found that fat tissue 
transplantation in mice was accompanied by a slight decrease in endogenous 
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epididymal WAT mass (9) suggesting that the artificial increase in fat mass may 
induce compensatory mechanism in order to restore normal total fat mass and body 
weight. However, little is known about potential mechanism involved in fat mass auto-
regulation. There is evidence that adipose tissue mass may be regulated either via 
humoral or neuronal signals originating from the hypothalamus (10; 11).  
  
 We previously developed a fat transplantation model in mice demonstrating a 
role for the transplantation site of WAT on glucose homeostasis (9; 12). 
Transplantation of epididymal WAT (eWAT) to a systemically drained acceptor site 
improved glucose tolerance in mice (9). In contrast, eWAT transplanted to a portal 
vein-drained acceptor site (pTx) deteriorated glucose tolerance and induced hepatic 
insulin resistance (IR) (12) providing direct evidence in support of the portal 
hypothesis. The latter proposes that the development of hepatic IR and liver steatosis 
results from direct exposure of the liver to increasing amounts of free fatty acids and 
pro-inflammatory factors released from visceral fat into the portal vein of obese 
patients (13). Preliminary observations from our studies suggested that not only 
insulin sensitivity but also other metabolic parameters are influenced by the site of 
transplantation. For example, endogenous epididymal WAT mass was slightly 
decreased in chow-fed mice receiving a systemically drained WAT transplant (9). In 
addition, we have evidence that this effect is dependent on the mass transplanted 
WAT. Herein, we explored the hypothesis that portal transplantation of eWAT alters 
endogenous WAT mass compared to sham operated animals and propose a 
potential role of adipose tissue-derived factors in the regulation of total body fat mass.  
 
Research Design and Methods 
 
Animals. Male C57BL/6JOlaHsd mice were purchased from Harlan Netherlands 
(Harlan, AD Horst, The Netherlands). All mice were housed in a pathogen-free 
environment on a 12-h light-dark cycle (lights on at 6am) and an ambient 
temperature of 22°C, with free access to standard rodent diet (diet 3430, Provimi 
Kliba, Kaiseraugst, Switzerland). Prior to sacrifice and tissue harvest, animals were 
fasted for 3 hours. Adipose tissue mass was evaluated from pooled samples of both 
epididymal, inguinal (iWAT), and retroperitoneal (rWAT) depots as well as total 
mesenteric depot per mouse. Transplanted fat pad weight was not included in 
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calculation. All protocols conformed to the Swiss animal protection laws and were 
approved by the Cantonal Veterinary Office in Zurich, Switzerland. 
 
Surgical procedure. Transplantation procedure was performed at 8 weeks of 
age as described (12). Briefly, mice were anaesthetized with isoflurane (Abbott, Baar, 
Switzerland). Both epididymal fat pads (total transplanted fat: ~280 mg [range 160-
400 mg]) were removed from the donor mouse, rinsed with 0.9% saline, and 
thereafter stitched to the mesenterium of the recipient mouse (portal transplantation, 
pTx) using Monocryl 6.0 (Johnson-Johnson, Spreitenbach, Switzerland). Sham-
operated control mice underwent the same surgical procedure without receiving a fat 
transplant. Therefore, tissues were briefly exposed and gently moved with forceps 
and afterwards repositioned. Subcutaneous (nuchal fold) injection of buprenorphine 
every 6-8 h for at least two days or until necessary was used for analgesia. To 
prevent transplant rejection, donor and recipient mice were littermates. In general, all 
animals tolerated surgery well. Subsequent analyses were done 4-5 weeks post 
transplantation. In total, 30 different litters in 7 cohorts were analysed. As proper re-
vascularisation and drainage site can only be evaluated post-mortem, several 
animals had to be excluded due to double-drainage, i.e. at least one of the grafts was 
clearly re-vascularised and attached to any site not draining to the portal vein (e.g. 
inner side of peritoneum or endogenous epididymal fat pad). These animals and their 
corresponding litter sham control animals were taken out completely from all 
analyses and evaluated separately (data not shown). Sham and pTx numbers are not 
equal as sometimes two pTx animals were operated from a litter of 5 animals. 
 
Indirect calorimetry. For metabolic phenotyping, mice were individually housed in 
plexiglass air-tight cages designed for open circuit calorimetry (PhenomasterTM, TSE 
Systems GmbH, Bad Homburg, Germany). Prior to starting measurement, animals 
were separated to accustom to single-caging for 48 hours and body weight was 
monitored twice daily. The system was calibrated prior to each run according to 
manufacturer’s instruction with known weights for food and drinking water as well as 
known gas concentrations for oxygen uptake and carbon dioxide production 
measurements. Sampling interval was 2 min per cage every 18 min measuring 8 
cages in a row and one reference cage and automatically recorded using the 
integrated software package. For time-course analysis, data were binned in 24 one 
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hour values. Locomotor activity data was recorded with a 2-dimensional infrared 
beam grid. Food and water intake were continuously monitored to the nearest 0.01 
gram or millilitre. Any visible residual spilled food pellets found in the cage after 
measurement period were weighed and deducted. Animals were fed standard chow 
with a metabolizeable energetic density of 3.14 kcal/g (3430, Provimi Kliba AG, 
Kaiseraugst, Switzerland). Data were collected for four 24-hour days. The first day 
was analysed separately, however, included in time course and cumulative analysis. 
In general, most values obtained were stable from day 2 to day 4 suggesting a 
steady-state in measured parameters. Values are expressed per mouse per day 
unless otherwise stated (14; 15). The first two lots of animals were only tested for a 
single day of metabolic cages, the 3rd and 4th lot for 2 days and the 5th and 6th lot 
for 4 consecutive days. Hence number of animals per day reduces and is indicated in 
the corresponding figures. 
 
Western blotting. Liver, eWAT and mWAT tissue were harvested and snap-frozen in 
liquid nitrogen and stored at -80°C until homogenization. Tissue samples were 
pulverized in liquid nitrogen and homogenized in a buffer containing 150 mM NaCl, 
50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1% NP-40, 0.25% sodium deoxycholate, 
1mM sodium vanadate, 1mM NaF, 10mM sodium β-glycerophosphate, 1 mM sodium 
pyrophosphate, 0.2 mM PMSF and a 1:1000 dilution protease inhibitor cocktail 
(P8340, Sigma Aldrich). Protein concentration was determined using BCA assay 
(Pierce, Rockford, IL), and equivalent amounts of protein (20–40 μg) were resolved 
by LDS-PAGE (4–12% gel, NuPAGE; Invitrogen) or self-casted 6-10% SDS gels. 
Proteins were electrotransferred onto nitrocellulose membranes (0.2 μm; Bio-Rad, 
Reinach, Switzerland) or PVDF membranes (0.45 μm; Roche Diagnostics GmbH, 
Mannheim, Germany), and equal loading was confirmed by Ponceau S staining. 
Membranes were blocked for one to two hours in 5% non fat dry milk (BioRad) 
resolved in Tris buffered saline, containing 0.1% Tween 20. Membranes were 
incubated over night at 4°C on a rocking platform with respective primary antibodies. 
The following primary antibodies were used: anti-pACCSer79, anti-ACC, anti-
pHSLSer660, anti-ATGL, anti-PPARγ (all from Cell Signaling Technology, Danvers, 
MA), anti-SREBP-1c, anti-CEBPβ, anti-CEBPα (all from Santa Cruz Biotechnology, 
Santa Cruz, CA), anti-pPerilipinSer522 (Vala Sciences, San Diego, CA), and anti-
actin (Millipore, Zug, Switzerland). Subsequently, membranes were incubated with 
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appropriate secondary antibody (horseradish peroxidase-conjugated; Santa Cruz 
Biotechnology) for 45 min at 37°C and 45 min at room temperature. Bands were 
detected after 5-10 minute incubation with Lumi-Light substrate (Roche) and 
subsequently exposed in an Image Reader and analyzed with Image Analyzer 
(FujiFilm, Dielsdorf, Switzerland). Protein expression was normalized to loading 
control actin. 
 
RNA extraction and quantitative RT-PCR. Total RNA was extracted from eWAT, 
iWAT, and mWAT as well as liver using the RNeasy Lipid Tissue Mini Kit (Qiagen, 
Basel, Switzerland), and concentration was determined spectrophotometrically 
(Nanodrop 1000; Nanodrop Technologies, Boston, MA). The integrity of each RNA 
sample was examined by Agilent Lab-on-a-chip technology using the RNA 
6000NanoLabChip kit and a bioanalyzer 2100 (both Agilent Technologies, Basel, 
Switzerland). An RNA integrity number >8.0 was considered as acceptable for further 
processing; 0.75–1 μg of RNA was reverse transcribed with Superscript III Reverse 
Transcriptase (Invitrogen, Basel, Switzerland) using a random hexamer primer 
(Invitrogen). Taqman (Applied Biosystems, Rotkreuz, Switzerland) was used for real-
time PCR amplification. The following PCR primers (Applied Biosystems) were used: 
Srebf1_Mm00550338_m1, Insig1_Mm00463389_m1, Fgf21_Mm00840165_g1, 
Ucp1_Mm01244861_m1, Cidea_Mm00432554_m1. Gene expression was calculated 
with standard curves included on each plate and is expressed relative to loading 
control 18sRNA (Applied Biosystems) and normalized to sham-operated animals. 
 
Microarray Experiment Description 
cDNA preparation. The quality of the isolated RNA was determined with a 
NanoDrop ND 1000 (NanoDropTechnologies, Delaware, USA) and a Bioanalyzer 
2100 (Agilent, Waldbronn, Germany). Only those samples with a 260 nm/280 nm 
ratio between 1.8–2.1 and a 28S/18S ratio within 1.5–2 were further processed.  
cDNA preparation was performed using the Ambion WT Expression Kit (P/N 
4411973) in a following manner: RNA samples (100 ng) were reverse-transcribed 
into double-stranded cDNA. Double-stranded cDNA was in vitro transcribed to cRNA. 
cRNA was purified using Nucleic Acid Binding Beads in a manner described in a 
protocol. cRNA yield and size distribution were determined using NanoDrop ND 1000 
and Bioanalyzer 2100. Sense-strand cDNA was synthesized by reverse transcription 
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of 10 μg of cRNA using random primers. RNase H was used to degrade cRNA 
template leaving single-stranded sense-strand cDNA. The sense-strand cDNA was 
purified using Nucleic Acid Binding Beads. The yield of cDNA was determined using 
NanoDrop ND 1000. 
Fragmentation and labeling was performed using AffymetrixGeneChip WT Terminal 
Labling Kit (P/N 901525) as described here. Fragmentation reaction with 5.5 μg of 
cDNA was followed by the labeling of the fragmented single-stranded cDNA in the 
presence of biotinylated nucleotides and terminal deoxynucleotidyltransferase (TdT) 
that catalyzes nontemplate-directed nucleotide incorporation onto the 3'-OH end of a 
single-stranded DNA. 
 
Array hybridization. Biotin-labeled cDNA samples were mixed in 150 μl of WT 
Hybridization Cocktail (Affymetrix, P/N 901667) containing a Hybridization Controls 
and Control Oligonucleotide B2 (Affymetrix, P/N 900454). Samples were hybridized 
to GeneChip® Mouse Gene 2.1ST Array Strip (Affymetrix, P/N 901628) in the 
GeneAtlas Hybridization Station for 20 h at 48°C. Arrays were then washed using 
AffymetrixGeneAtlas Fluidics Station. An AffymetrixGeneAtlas Imaging Station was 
used to measure the fluorescent intensity emitted by the labeled target. 
 
Analsis of microarray data. The resulting CEL files have been analyzed using 
Bioconductor/R. In particular the steps included RMA summarization (16), quality 
control in order to check the similarity of samples within the groups and the 
distinction between the groups and then pairwise comparisons between groups. In 
the case of t-test in pairwise comparisons, the false discovery rate was controlled 
using Benjamini-Hochberg correction (17). A p-value of 0.1 for trendwise and 0.05 for 
significant changes together with a fold-change of 1.4 was taken as cut-off value 
between both groups for gene expression analysis. 
 
Data analysis. Data are presented as mean ± standard deviation. General analysis: 
Statistical analyses were performed using Student’s t-test or Mann-Whitney U test 
where appropriate. Log transformation was used if data were not normalized. 
Metabolic cage analysis: As energy expenditure is dependent on body mass, an 
ANCOVA was used with body mass (BM) as co-variable (14; 18; 19). Additionally, as 
weight stability is assumed during evaluation of parameters in metabolic cages (e.g. 
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20), delta BM (∆BM) was used as a second co-variable for statistical evaluation. 
Animals BM during metabolic cage evaluation remained, however, quite stable (sham 
= -0.38 ± 0.54 g vs. pTx = -0.3 ± 0.76 g) and hence ∆BM co-variable analysis 
revealed no further major adjustments and is therefore omitted from results. For 
clarity, relevant data are presented with and without correction. P values <0.05 were 
considered significant. The software in use for graphical analysis was Prism Version 
5.0 (GraphPad Software Inc.,San Diego, CA, USA). Statistical evaluation was done 
with SPSS 21 (IBM). 
 
Results 
 
Endogenous WAT mass is increased in pTx transplanted mice 
At the time of surgery, body mass did not differ between pTx and sham-
operated mice. Additionally, body mass gain from time of surgical intervention until 
sacrifice was similar between both groups (Table 1). Of note, body mass in these 
chow-fed animals was not related to total fat pad mass, neither in total nor in sub-
group analyses (Fig.1 A-C). In contrast, endogenous adipose tissue mass defined by 
the four indicated depots differed between the groups. There was a significant 
increase in total endogenous WAT mass in pTx vs. sham-operated animals (Table 1). 
Subgroup analysis of the four depots showed significant differences for mWAT and a 
strong trend for eWAT (Fig. 1 D). Of note, mass of transplanted fat pads decreased 
by about 30% from 277±66 mg to 188±51 mg. Therefore, portal transplantation of 
WAT increases endogenous fat mass in acceptor mice.  
 
No differences in food intake and energy expenditure between pTx and sham-
operated mice 
To assess potential differences in food intake and/or energy expenditure, mice 
were housed in metabolic cage units for up to 96 hours. As depicted in Table 1, 
neither food intake (FI), nor energy expenditure (EE), nor activity differed significantly 
between both groups on any day of evaluation. Additionally, day-night patterns did 
not show any alterations between the two groups (data not shown). Time course 
analysis over sampling period is demonstrated in Figures 2 A to C. There seems to 
be a diverging trend between the groups when evaluated over longer periods. 
Unfortunately, we could not prolong housing time in metabolic cages to study 
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whether the curves of cumulative FI would continue spreading as time of single cage 
housing was limited to a total of 6 days including adaptation for ethical reasons. 
Additionally, number of animals per day decreased (see methods section) and 
therefore may have biased our result due to the small cohort sampled. 
 
Microarray data  
Since mWAT and eWAT mass differed between both groups (Fig. 1), these 
two tissues were screened with microarray analysis for potential gene candidates, 
which could explain observed differences in phenotype. Genes that were altered 
between pTx and sham-operated mice are depicted in Table 2 and Table 3 for eWAT 
and mWAT, respectively. We did not observe major differences for any known 
pathways involved in regulating WAT mass between both groups. Manual inspection 
of raw data did not identify any further genes mainly due to high intra-group variation 
for some potential targets. A fold change of 1.4 (2^0.5) was considered as relevant 
between the two groups. However, Benjamini-Hochberg corrected FDR setting of 5% 
revealed no single gene to be altered in either tissue. Metacore® pathway analysis 
revealed no consecutive pathways to be altered.  
 
Similar expression of Ucp1, Cidea, Fgf21 and Insig1 in eWAT of pTx and sham-
operated mice  
Due to unproductive microarray analysis, we focused on some targets 
previously reported to contribute to browning (appearance of brown adipocytes in 
WAT leading to increased energy expenditure) of iWAT or to WAT mass regulation. 
We did not observe any differences in Ucp-1 or Cidea expression in iWAT between 
both groups excluding differences in its browning capacity and matching results 
obtained for energy expenditure (Table 1). In addition, Fgf21, which was shown to be 
increased in obese humans and patients with T2DM (21) and found to control energy 
expenditure and insulin action in mice (22; 23), was expressed at very low levels in 
liver and did not differ between both groups. However, its role may be more complex 
with different functions in human and mouse (24). Moreover, the Insig1-SREBP1-
SCD1 pathway was recently reported to regulate WAT mass (25). As depicted in Fig. 
3 A-C, Insig1 and Srebf1 expression did not differ between pTx and sham-operated 
mice. 
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 No alterations of protein level in eWAT of pTx mice  
Phosphorylation state or total protein levels of major regulators of fatty acid 
(FA) and/or triglyceride (TG) metabolism was assessed next. Neither phosphorylation 
state of hormone-sensitive lipase (HSL) and perilipin, nor total protein concentration 
of adipose triglyceride lipase (ATGL) was altered (Fig. 4). Similarly, phosphorylation 
of Acetyl-CoA carboxylase (ACC), which is the main regulator for Malonyl-CoA 
production, or its total protein level did not differ between both groups (Fig 4). Next 
master regulators of WAT development were assessed. Unexpectedly, neither 
peroxisome proliferator-activated receptor γ (PPARγ) nor any of the other main up- or 
downstream regulators like CCAAT/enhancer-binding protein alpha (CEBPα) or beta 
(CEBPβ), or sterol regulatory element-binding protein 1c (SREBP-1c) showed any 
difference at protein level. 
 
Discussion 
 
The present study sought to explore the effect of portal vein-drained white 
adipose tissue transplantation on whole body energy metabolism and its regulatory 
effect on endogenous white adipose tissue mass. It demonstrates that exogenously 
transplanted portal drained white adipose tissue is increasing endogenous WAT 
mass in chow-fed mice by yet unknown mechanisms. No differences in food intake, 
energy expenditure, or activity between sham-operated and pTx mice were observed. 
Similarly, no gross changes in endogenous WAT’s gene expression profile explaining 
the observed phenotype could be identified. Neither could alterations in protein levels 
or phosphorylation states thereof be identified to explain the increased endogenous 
eWAT mass. 
The increase in endogenous WAT mass could have been the result of 
increased food intake or decreased energy expenditure; however, none of these 
parameters varied significantly between pTx and sham-operated mice during the 
four-day observation period. Such finding does not rule out the possibility that over a 
longer observation period, subtle differences in FI and/or EE may have occurred. 
Indeed, there seemed to be a diverging pattern of cumulative FI between the two 
groups with a surprisingly lower cumulative FI in pTx animals (Fig. 2A), whereas 
absolute cumulative values either after 3 or 4 days did not reveal any statistical 
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difference (Table 1). It should be noted that number of animals decreased per day 
since, initially, mice were not tested for four days (see also methods). However, it 
seems rather unlikely that small changes in FI or EE are at all detectable due to large 
inter-individual and inter-litter variations. FI for example varied between 1.5 and 3.7 g 
during day 1 (i.e. when animals were more stressed due to placement from 
adaptation into measurement cages) and between 2.5 and 4.8 g during subsequent 
days 2-4 when FI was stable for individual mice.  
It was previously reported that transplantation of eWAT to subcutaneous 
location reduced endogenous WAT mass without gross changes in body composition, 
body weight or FI (8; 9). In contrast, we demonstrated herein that transplantation of 
portal vein-drained adipose tissue increased endogenous WAT mass without 
affecting body weight or FI. Such findings points towards a crucial role for drainage 
site of adipose transplants on whole body fat mass regulation: transplants in the 
studies by Rooks et al. (8) and Konrad et al. (9) were drained systemically and 
resulted in reduced endogenous fat mass whereas transplants reported herein were 
drained into the portal vein resulting in increased endogenous WAT mass. These 
data may suggest that endogenous fat tissue may have the ability to control total 
body fat mass. Such control mechanism appears to be dependent on venous 
drainage of fat tissue, as it remains intact in mice receiving a systemically drained, 
but not in mice receiving a portally drained fat transplant. It is conceivable that factors 
released by adipose tissue (or the fat transplant) are extracted by their first liver 
passage and thereby their effect on fat mass control is lost.  
Of note, in our previous study (12), we did not observe a major influence of 
portal vein-drained adipose tissue transplants on endogenous WAT mass. In contrast 
to the study presented herein, mass of transplanted WAT was approximately half of 
the amount used in the current study (~150 mg vs. ~280 mg) suggesting a dose-
dependence and/or a “threshold” amount of transplanted fat tissue necessary to 
cause feedback mechanisms involved in sensing WAT mass. In contrast, 
development of glucose intolerance was not influenced by the amount of WAT mass 
transplanted since glucose tolerance was similarly impaired in the previous 
compared to the current study (data not shown). The notion of a certain “threshold” 
for sensing increased WAT mass is supported by a study from Foster et al. (26). In 
the latter study, 100-150 mg of either mWAT or eWAT was transplanted to the 
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intestine (i.e. to a portal vein-drained location) of mice resulting in a small but non-
significant increase in endogenous fat mass.  
Potentially, physical attachment of the two fat pads to the intestine may have 
affected intestinal motility or food absorption thereby impacting on FI either via 
modulation of intestinal vagal afferent signals to the brain or via inhibition of liver lipid 
oxidation (11). Our metabolic data, however, do not support such notion since neither 
food intake nor energy expenditure were different between pTx and sham-operated 
mice. Nevertheless, occurrence of nutrient mal-absorption and subsequent 
alterations of central feedback mechanisms cannot be ruled out in pTx mice since 
fecal composition and energetic value were not determined. Likewise, loss of 
innervation and/or re-innervation of transplanted adipose tissue may have affected 
endogenous fat mass since WAT innervation was proposed to sense WAT mass and 
contribute to its regulation (27-30).  
Protein levels of PPARγ, which is considered as master regulator of 
adipogenesis (31; 32), were not altered to great extent in endogenous eWAT of both 
pTx and sham-operated control mice. Likewise, protein concentrations of upstream 
transcription factors such as CEBPβ and CEBPα were not changed either. Similarly, 
Srebf1 and SREBP-1c levels were not different between sham-operated and pTx 
mice suggesting that other mechanisms are primarily involved. However, this does 
not rule out the possibility that alterations in posttranslational 
modification/degradation of PPARγ such as ubiquitination or SUMOylation or that 
stress kinases like extracellular signal-regulated kinase (ERK) or p38 mitogen-actived 
protein kinase (MAPK) may influence PPARγ phosphorylation and hence impact on 
its activity level. An alteration of PPARγ or its activity would suggest an increase in 
WAT mass via hyperplastic response. We did not measure adipocyte size and 
number herein so far, but we previously did not observe any differences in fat cell 
size of eWAT and mWAT as evaluated from histological sections between pTx and 
sham-operated mice (12). However, a hypertrophic response cannot be ruled out and 
needs to be evaluated in future. Assuming that there was no difference in adipocyte 
size in the present study the increase in adipose tissue mass would suggest an 
increase in adipocyte number and, thus, rather a hyperplastic response, possibly 
downstream of PPARγ. Hence targets like lipoprotein lipase, fatty-acid transport 
protein, phosphoenolpyruvate carboxykinase or glycerol kinase need to be assessed 
to support such notion (32). 
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In summary, results presented herein demonstrate an increase in endogenous 
fat mass in mice receiving a portal vein-drained adipose tissue transplant. 
Accumulating evidence suggest that endogenous fat tissue may have the ability to 
control total body fat mass. However, such control mechanism may appear to be 
dependent on venous drainage of fat tissue, as it remains intact in mice receiving a 
systemically drained, but not in mice receiving a portally drained fat transplant. Due 
to the complexity of the model and the rather small changes in WAT mass in chow-
fed animals, involved mechanisms may be difficult to identify. It is conceivable that 
factors released by adipose tissue (or the fat transplant) are extracted by their first 
liver passage and thereby their effect on food intake/energy expenditure is lost. 
Alternatively, neural feedback loops involving liver, brain and white adipose tissue 
that are involved in sensing an increase in adipose tissue mass may be disturbed in 
pTx mice. 
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Figure Legends 
 
Fig. 1 Correlation of body mass at sacrifice with adipose tissue mass of dissected 
depots for all animals (n = 41) analyzed (A) and split-up by groups for sham (B, n = 
19) and portal-transplanted (C, n = 22) animals is depicted. Weights of different fat 
depots in sham (●) and portal-transplanted (▲) animals (D). Data are scatter plots 
with mean + SD for n = 19-22 animals. P-values of Student’s t test or Mann-Whitney-
U test are indicated above each fat depot. 
 
Fig. 2 Cumulative food intake (g/mouse) is indicated over a period of 96 hours. Of 
note, number of animals decreases from day 1 (n=10 sham vs. 12 pTx) to day 4 (n=5 
sham vs. 7 pTx) (A). Time course analysis for energy expenditure (cal/h) for 96 hours 
is indicated (B). Total ambulatory activity in a 2-D grid (total beam interruptions/h) is 
indicated for a period of 96 hours (C).  
 
Fig. 3 Semi-quantitative gene expression analysis of uncoupling-protein 1 (Ucp-1) 
and Cidea in inguinal white adipose tissue (iWAT) (A), fibroblast growth factor 21 
(Fgf21) in liver (B) and sterol regulatory element-binding factor 1 (Srebf1) as well as 
insulin-induced gene 1 (Insig1) in epididymal white adipose tissue (eWAT) is shown 
(C) for sham (●) and pTx (▲) animals. Data are scatter plots with mean + SD of n = 7 
animals per group.  
 
Fig. 4 Protein levels in epididymal white adipose tissue (eWAT) for indicated proteins 
or phosphorylation state of indicated proteins is shown. Semi-quantitative data 
normalized to the expression level of actin are indicated below for sham (black bars) 
and pTx (open bars) animals and represent mean + SD of n = 7 animals per group.  
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6. General discussion 
 
During the time course of performing the experiments for this thesis starting in 
2010, several other studies have been published (54-56; 210-215) concerning the 
influence of a short bout of HFD-feeding on the development of IR and other 
important parameters, which may respond instantaneously on this dietary challenge, 
partly supporting and contradicting the results presented herein. Subsequently, our 
findings will be compared to these studies and further implications will be discussed. 
Studies performed with short time periods of challenging mice or rats with HFD 
in the range of 2-7 days showed smaller or larger contributions of the innate immune 
system to the development of IR at this early stage. Apparently, mouse-strain 
dependent reaction in general on HFD feeding (216) and possibly also on the short-
term overfeeding does play a role even in the commonly used C57BL/6 strain as 
publications do not clearly indicate if there is e.g. WAT expansion at such early 
phase and if, together with its underlying functional changes, this contributes as a 
single factor to the development of IR in susceptible animals (217). This, together 
with the inherent properties of WAT depots (86) as well as reactivity and predictability 
of gene alterations in a HFD-setting (215), and tissue specificity in reaction proven in 
long-term DIO mice for WAT, muscle, liver, and heart (218), may contribute to the 
differences in findings between papers published. 
In general, it turns out that liver is the primary and first organ to develop insulin 
resistance as early as 3-4 days after initiating HFD feeding (56; 214; 219), which is in 
accordance with our data. Interestingly, two studies (56; 214) did not find an 
aggravation of whole body glucose intolerance as assessed by a glucose tolerance 
test after 3 days of HFD-feeding. However, these findings do not exclude that 
different mechanisms causing this state of insulin resistance are involved at later 
stages of HFD-induced IR. 
Subsequently, after 7 days of HFD-feeding, WAT may become insulin 
resistant as assessed by hyperinsulinaemic-euglycaemic clamp technique, and, 
similarly as liver, its insulin resistance was not further aggravated during continuous 
HFD feeding (214). At least in a shorter setting, i.e. 3-4 days, WAT seems to remain 
fully functional as could be shown in our study and more recently in another 
publication (54). However, a further study suggested impaired WAT lipolytic activity 
regulated by central mechanism due to the development of brain insulin resistance 
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(213). Apparently, discerning central and peripheral insulin action in this short-term 
HFD setting at the same time could resolve these paradox findings. The functionality 
of WAT seems to persist despite showing a certain degree of inflammation as 
assessed by gene expression levels of pro-inflammatory cytokines in several studies 
together with adipose tissue mass expansion (54-56). The latter effect may occur 
dependent (54-56) or independent (214) of total body mass changes or do not occur 
at all as was demonstrated in our animals. Again, it is pretty likely that the effect of 
increased body weight gain during this short period of HFD-feeding and the 
dependent or independent effect of WAT mass increase may not be causally 
involved in the development of glucose intolerance or insulin resistance, at least 
nicely shown for the development of central insulin resistance (210) but that rather 
inherent production and release of cytokines (54), a switch in dynamic immune 
response as evidenced by activation of adipose-resident NKT cells (55) or transient 
neutrophil infiltration (220) play a major role at this early stage. 
Similarly, lipid overload in tissues and circulation either by acute infusion of 
lipids (221; 222) or in these short-term HFD settings (54-56), which are known to lead 
to a transient hyperphagic response (223; 224), altering circadian rhythm (212) and 
stimulate anorexigenic mechanisms (211), is also suggested to be causally linked to 
the development of both hepatic and total body insulin resistance. Interestingly, other 
theories propose that the development of hepatic insulin resistance is rather a 
defence mechanism against further aggravation of disease development (225). 
Apparently, lipid overload may either cause or contribute to the development of 
insulin resistance at various degrees in different tissues. Turner et al. (214) observed 
liver TAG and DAG to be elevated after one week of HFD-feeding without alterations 
of ceramide levels, which are known to be able to directly interfere with insulin 
signalling. WAT may be otherwise affected as neither TAG nor DAG but rather 
number of ceramides and sphingomyelins were elevated. Furthermore, skeletal 
muscle lipid content was not altered until skeletal muscle insulin resistance 
developed after three weeks of HFD-feeding in their study. Furthermore, the 
possibility exists that there are also time-dependent compensations or alterations of 
liver lipid content, which can contribute to the degrees of hepatic insulin resistance 
(226). It is likely that this may explain the shift towards higher lipid contents in 
skeletal muscle and WAT at later stages observed by Turner et al. (214). 
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This strongly suggests different roles of tissue lipid overload in the three main 
insulin-responsive tissues and hence our data, which discern development of hepatic 
steatosis from inflammation, demonstrate further the complexity of correctly 
pinpointing the underlying reason in the development of insulin resistance. 
 Hence, to date it remains still impossible to exactly trigger the initial 
mechanism leading to the development of hepatic insulin resistance at the very 
beginning of an obesogenic HFD-challenge. Possibly WAT inflammation and lipid 
accumulation in target tissues play a concomitant role in exaggerating each other
s 
single effect on insulin signalling and inter-organ cross talk is continuously involved in 
this process (69). 
 
Similarly, transplanting WAT has gained attention in different contexts by 
several studies (227-233). The study of Foster et al. (227) confirmed previous 
findings that eWAT removal is a powerful signal for other fat depots to increase 
endogenous mass, something that has been known in rodents for decades (234). 
Their findings also suggested that for true visceral adipose tissue, i.e. mWAT, less fat 
mass needs to be removed when compared to eWAT to exert positive effects on 
glucose metabolism. However, their study did not demonstrate any negative 
regulatory effects of portal transplanted mWAT on fat mass. This may have been due 
to the small mass of transplanted tissue, which may be below a certain threshold 
necessary to exert regulatory responses. Similarly, the same group performed a 
series of different donor tissue transplantations into the visceral cavity by attaching 
these autologous fat pads to endogenous mesenteric adipose tissue using tissue 
glue (228). Hence, it is likely that these fat pads may exert their effect also via the 
endogenous mWAT as direct WAT-WAT interaction may have occurred (235; 236). 
Despite reporting a positive effect of transplanting iWAT to the mesentery on hepatic 
glucose and lipid metabolism, and only a statistical measurable increase in rWAT 
when mWAT was transplanted and eWAT when iWAT was transplanted, the authors 
did not observe any other alterations of endogenous WAT mass. This again may 
have been due to the low amount of transplanted fat (~100 to 150mg), much less 
than was used in the current study (~280mg). Nevertheless, these studies 
demonstrate that transplantation of different WAT depots into the visceral cavity 
draining into the portal vein exerts alterations on endogenous WAT depots and 
functions (234; 237). 
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WAT transplantation has been recently suggested to protect in part from 
spontaneously developing T1DM in BB/OK rats (229). In this study, the authors took 
eWAT and transplanted it into subcutaneous sites, which was previously shown to 
exert positive effects on whole body metabolism (65). Similarly, Gunawardana et al. 
(238) found that mice were protected from developing streptozotocin-induced T1DM 
after transplanting BAT into subcutaneous locations. In both studies, normalizing 
WAT function seemed to be a major mechanism for protecting against T1DM. 
However, none of the studies assessed transplantation-induced endogenous WAT 
mass alterations in these T1DM models. 
Barrera et al. (230) used an interesting approach of injecting eWAT of 12-
week HFD-fed animals into recipient mice either into subcutaneous area or directly 
into recipient eWAT. At least the latter approach may have led to increases in the 
endogenous eWAT depot additional to having intact sympathetic nervous innervation 
- a suggested sensor of WAT mass. Of note, eWAT injection lead to deterioration of 
glucose and insulin tolerance as well as increased body weight gain suggesting that 
HFD-fed donor tissue triggers powerful signals when transplanted into the “wrong” 
side as subcutaneously grafted animals remained similar to control animals. However, 
these authors also did not test for endogenous WAT mass alterations which would 
have been a valuable point in discerning “unhealthy”, i.e. diet-induced obese WAT, 
function from transplant location. 
A study similar to ours (231) found increased portal IL-1β to be not only a 
regulator of hepatic gluconeogenic flux but also critical for suppressing WAT mass 
expansion as IL-1β knockout animals demonstrated higher eWAT mass in both 
chow-fed and HFD-fed conditions. We have not tested IL-1β’s role in our animals so 
far. 
Lastly, the study of Zhao et al. (232) points to a crucial role of 
neovascularisation of fat grafts for their function and survival. Although their study 
does not report completely new findings (239), it reminds us that 
neovascularisation/revascularisation of fat transplant should be more frequently 
assessed in further research studies to be able to better compare outcomes of 
different fat grafts, their inherent characteristics, and their transplantation site-
dependent effects on metabolism. 
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Collectively, the projects of this PhD thesis add to the body of evidence that 
WAT exerts a myriad of functions and contributes greatly to the development of 
obesity-associated insulin resistance. Beyond that, it has powerful auto-regulatory 
mechanism to control its own mass and this ability may be in part dependent on its 
drainage site. 
 
 
 70
7. References 
 
1. http://www.who.int/mediacentre/factsheets/fs311/en/. (accessed March 2014) 
2.  Ryan KK, Woods SC, Seeley RJ: Central nervous system mechanisms linking 
the consumption of palatable high-fat diets to the defense of greater adiposity. 
Cell Metab 15:137-149, 2012 
3.  https://apps.who.int/infobase/. (accessed March 2014) 
4.  WHO: Global status report on noncommunicable diseases 2010. Geneva, 
WHO Press, 2011 
5.  Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: 
estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-
1053, 2004 
6.  Walley AJ, Asher JE, Froguel P: The genetic contribution to non-syndromic 
human obesity. Nat Rev Genet 10:431-442, 2009 
7.  Friedman JM: A war on obesity, not the obese. Science 299:856-858, 2003 
8.  Wadden TA, Considine RV, Foster GD, Anderson DA, Sarwer DB, Caro JS: 
Short- and long-term changes in serum leptin dieting obese women: effects of 
caloric restriction and weight loss. J Clin Endocrinol Metab 83:214-218, 1998 
9. Wajchenberg BL: Subcutaneous and visceral adipose tissue: their relation to 
the metabolic syndrome. Endocr Rev 21:697-738, 2000 
10. Misra A, Vikram NK: Clinical and pathophysiological consequences of 
abdominal adiposity and abdominal adipose tissue depots. Nutrition 19:457-
466, 2003 
11.  Flegal KM, Kit BK, Orpana H, Graubard BI: Association of all-cause mortality 
with overweight and obesity using standard body mass index categories: a 
systematic review and meta-analysis. JAMA 309:71-82, 2013 
12. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, 
Mookadam F, Lopez-Jimenez F: Association of bodyweight with total mortality 
and with cardiovascular events in coronary artery disease: a systematic review 
of cohort studies. Lancet 368:666-678, 2006 
13.  Hughes V: The big fat truth. Nature 497:428-430, 2013 
14.  Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett 
J, Sowers MR: The obese without cardiometabolic risk factor clustering and 
the normal weight with cardiometabolic risk factor clustering: prevalence and 
correlates of 2 phenotypes among the US population (NHANES 1999-2004). 
Arch Intern Med 168:1617-1624, 2008 
15.  Ahima RS, Lazar MA: Physiology. The health risk of obesity--better metrics 
imperative. Science 341:856-858, 2013 
16.  Unger RH, Scherer PE: Gluttony, sloth and the metabolic syndrome: a 
roadmap to lipotoxicity. Trends Endocrinol Metab 21:345-352, 2010 
17.  Enerback S: Adipose tissue metabolism in 2012: Adipose tissue plasticity and 
new therapeutic targets. Nat Rev Endocrinol 9:69-70, 2013 
18.  Chechi K, Nedergaard J, Richard D: Brown adipose tissue as an anti-obesity 
tissue in humans. Obes Rev 15:92-106, 2014 
19.  Smorlesi A, Frontini A, Giordano A, Cinti S: The adipose organ: white-brown 
adipocyte plasticity and metabolic inflammation. Obes Rev 13 Suppl 2:83-96, 
2012 
20. Lidell ME, Betz MJ, Dahlqvist Leinhard O, Heglind M, Elander L, Slawik M, 
Mussack T, Nilsson D, Romu T, Nuutila P, Virtanen KA, Beuschlein F, 
 71
Persson A, Borga M, Enerback S: Evidence for two types of brown adipose 
tissue in humans. Nat Med 19:631-634, 2013 
21.  Cypess AM, White AP, Vernochet C, Schulz TJ, Xue R, Sass CA, Huang TL, 
Roberts-Toler C, Weiner LS, Sze C, Chacko AT, Deschamps LN, Herder LM, 
Truchan N, Glasgow AL, Holman AR, Gavrila A, Hasselgren PO, Mori MA, 
Molla M, Tseng YH: Anatomical localization, gene expression profiling and 
functional characterization of adult human neck brown fat. Nat Med 19:635-
639, 2013 
22.  Sharp LZ, Shinoda K, Ohno H, Scheel DW, Tomoda E, Ruiz L, Hu H, Wang L, 
Pavlova Z, Gilsanz V, Kajimura S: Human BAT possesses molecular 
signatures that resemble beige/brite cells. PLoS One 7:e49452, 2012 
23.  Nedergaard J, Bengtsson T, Cannon B: New powers of brown fat: fighting the 
metabolic syndrome. Cell Metab 13:238-240, 2011 
24.  Slavin BG: Fine structural studies on white adipocyte differentiation. Anat Rec 
195:63-72, 1979 
25.  Robelin J: Cellularity of bovine adipose tissues: developmental changes from 
15 to 65 percent mature weight. J Lipid Res 22:452-457, 1981 
26.  Henry Y: Morphological and Metabolic Development of Adipose-Tissue in Pig 
as Affected by Selection, Feeding and Management. Annales De Biologie 
Animale Biochimie Biophysique 17:923-952, 1977 
27.  Poissonnet CM, Burdi AR, Bookstein FL: Growth and development of human 
adipose tissue during early gestation. Early Hum Dev 8:1-11, 1983 
28.  Harrington TAM, Thomas EL, Frost G, Modi N, Bell JD: Distribution of adipose 
tissue in the newborn. Pediatric Research 55:437-441, 2004 
29.  Gregoire FM, Smas CM, Sul HS: Understanding adipocyte differentiation. 
Physiol Rev 78:783-809, 1998 
30.  MacDougald OA, Mandrup S: Adipogenesis: forces that tip the scales. Trends 
Endocrinol Metab 13:5-11, 2002 
31.  Poulos SP, Hausman DB, Hausman GJ: The development and endocrine 
functions of adipose tissue. Mol Cell Endocrinol 323:20-34, 2010 
32.  Hausman GJ, Richardson RL: Adipose tissue angiogenesis. J Anim Sci 
82:925-934, 2004 
33.  Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, 
Blomqvist L, Hoffstedt J, Naslund E, Britton T, Concha H, Hassan M, Ryden M, 
Frisen J, Arner P: Dynamics of fat cell turnover in humans. Nature 453:783-
787, 2008 
34.  Gesta S, Tseng YH, Kahn CR: Developmental origin of fat: tracking obesity to 
its source. Cell 131:242-256, 2007 
35.  White UA, Stephens JM: Transcriptional factors that promote formation of 
white adipose tissue. Mol Cell Endocrinol 318:10-14, 2010 
36.  Camp HS, Ren D, Leff T: Adipogenesis and fat-cell function in obesity and 
diabetes. Trends Mol Med 8:442-447, 2002 
37.  Farmer SR: Transcriptional control of adipocyte formation. Cell Metab 4:263-
273, 2006 
38.  Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, 
Evans RM: PPAR gamma is required for placental, cardiac, and adipose tissue 
development. Mol Cell 4:585-595, 1999 
39.  Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman 
BM, Mortensen RM: PPAR gamma is required for the differentiation of adipose 
tissue in vivo and in vitro. Mol Cell 4:611-617, 1999 
 72
40.  Koutnikova H, Cock TA, Watanabe M, Houten SM, Champy MF, Dierich A, 
Auwerx J: Compensation by the muscle limits the metabolic consequences of 
lipodystrophy in PPAR gamma hypomorphic mice. Proc Natl Acad Sci U S A 
100:14457-14462, 2003 
41.  Zhang J, Fu M, Cui T, Xiong C, Xu K, Zhong W, Xiao Y, Floyd D, Liang J, Li E, 
Song Q, Chen YE: Selective disruption of PPARgamma 2 impairs the 
development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci U S 
A 101:10703-10708, 2004 
42.  Wang ND, Finegold MJ, Bradley A, Ou CN, Abdelsayed SV, Wilde MD, Taylor 
LR, Wilson DR, Darlington GJ: Impaired energy homeostasis in C/EBP alpha 
knockout mice. Science 269:1108-1112, 1995 
43.  Linhart HG, Ishimura-Oka K, DeMayo F, Kibe T, Repka D, Poindexter B, Bick 
RJ, Darlington GJ: C/EBPalpha is required for differentiation of white, but not 
brown, adipose tissue. Proc Natl Acad Sci U S A 98:12532-12537, 2001 
44.  Wu Z, Rosen ED, Brun R, Hauser S, Adelmant G, Troy AE, McKeon C, 
Darlington GJ, Spiegelman BM: Cross-regulation of C/EBP alpha and PPAR 
gamma controls the transcriptional pathway of adipogenesis and insulin 
sensitivity. Mol Cell 3:151-158, 1999 
45.  Cao Z, Umek RM, McKnight SL: Regulated expression of three C/EBP 
isoforms during adipose conversion of 3T3-L1 cells. Genes Dev 5:1538-1552, 
1991 
46.  Yeh WC, Cao Z, Classon M, McKnight SL: Cascade regulation of terminal 
adipocyte differentiation by three members of the C/EBP family of leucine 
zipper proteins. Genes Dev 9:168-181, 1995 
47.  Wu Z, Xie Y, Bucher NL, Farmer SR: Conditional ectopic expression of C/EBP 
beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis. 
Genes Dev 9:2350-2363, 1995 
48.  Sarjeant K, Stephens JM: Adipogenesis. Cold Spring Harb Perspect Biol 
4:a008417, 2012 
49.  Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, 
Jr.: Obesity is associated with macrophage accumulation in adipose tissue. J 
Clin Invest 112:1796-1808, 2003 
50. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross 
JS, Tartaglia LA, Chen H: Chronic inflammation in fat plays a crucial role in the 
development of obesity-related insulin resistance. J Clin Invest 112:1821-1830, 
2003 
51. Caspar-Bauguil S, Cousin B, Galinier A, Segafredo C, Nibbelink M, Andre M, 
Casteilla L, Penicaud L: Adipose tissues as an ancestral immune organ: site-
specific change in obesity. FEBS Lett 579:3487-3492, 2005 
52. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, Lee J, Goldfine 
AB, Benoist C, Shoelson S, Mathis D: Lean, but not obese, fat is enriched for 
a unique population of regulatory T cells that affect metabolic parameters. Nat 
Med 15:930-939, 2009 
53.  Sun S, Ji Y, Kersten S, Qi L: Mechanisms of inflammatory responses in obese 
adipose tissue. Annu Rev Nutr 32:261-286, 2012 
54.  Hadad N, Burgazliev O, Elgazar-Carmon V, Solomonov Y, Wueest S, Item F, 
Konrad D, Rudich A, Levy R: Induction of cytosolic phospholipase a2alpha is 
required for adipose neutrophil infiltration and hepatic insulin resistance early 
in the course of high-fat feeding. Diabetes 62:3053-3063, 2013 
 73
55.  Ji Y, Sun S, Xia S, Yang L, Li X, Qi L: Short term high fat diet challenge 
promotes alternative macrophage polarization in adipose tissue via natural 
killer T cells and interleukin-4. J Biol Chem 287:24378-24386, 2012 
56.  Lee YS, Li P, Huh JY, Hwang IJ, Lu M, Kim JI, Ham M, Talukdar S, Chen A, 
Lu WJ, Bandyopadhyay GK, Schwendener R, Olefsky J, Kim JB: Inflammation 
is necessary for long-term but not short-term high-fat diet-induced insulin 
resistance. Diabetes 60:2474-2483, 2011 
57.  Mallat Z: The B-side story in insulin resistance. Nat Med 17:539-540, 2011 
58.  Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Paltser G, Tsui H, Wu P, 
Davidson MG, Alonso MN, Leong HX, Glassford A, Caimol M, Kenkel JA, 
Tedder TF, McLaughlin T, Miklos DB, Dosch HM, Engleman EG: B cells 
promote insulin resistance through modulation of T cells and production of 
pathogenic IgG antibodies. Nat Med 17:610-617, 2011 
59.  Tchernof A, Belanger C, Morisset AS, Richard C, Mailloux J, Laberge P, 
Dupont P: Regional differences in adipose tissue metabolism in women: minor 
effect of obesity and body fat distribution. Diabetes 55:1353-1360, 2006 
60.  Tchkonia T, Thomou T, Zhu Y, Karagiannides I, Pothoulakis C, Jensen MD, 
Kirkland JL: Mechanisms and metabolic implications of regional differences 
among fat depots. Cell Metab 17:644-656, 2013 
61.  Bjorntorp P: The regulation of adipose tissue distribution in humans. Int J 
Obes Relat Metab Disord 20:291-302, 1996 
62.  Item F, Konrad D: Visceral fat and metabolic inflammation: the portal theory 
revisited. Obes Rev 13 Suppl 2:30-39, 2012 
63.  Berry DC, Stenesen D, Zeve D, Graff JM: The developmental origins of 
adipose tissue. Development 140:3939-3949, 2013 
64.  Tran TT, Kahn CR: Transplantation of adipose tissue and stem cells: role in 
metabolism and disease. Nat Rev Endocrinol 6:195-213, 2010 
65.  Tran TT, Yamamoto Y, Gesta S, Kahn CR: Beneficial effects of subcutaneous 
fat transplantation on metabolism. Cell Metab 7:410-420, 2008 
66.  Sun K, Kusminski CM, Scherer PE: Adipose tissue remodeling and obesity. J 
Clin Invest 121:2094-2101, 2011 
67.  Wueest S, Schoenle EJ, Konrad D: Depot-specific differences in adipocyte 
insulin sensitivity in mice are diet- and function-dependent. Adipocyte 1:153-
156, 2012 
68.  Rebuffe-Scrive M, Andersson B, Olbe L, Bjorntorp P: Metabolism of adipose 
tissue in intraabdominal depots of nonobese men and women. Metabolism 
38:453-458, 1989 
69.  Lee DE, Kehlenbrink S, Lee H, Hawkins M, Yudkin JS: Getting the message 
across: mechanisms of physiological cross talk by adipose tissue. Am J 
Physiol Endocrinol Metab 296:E1210-1229, 2009 
70.  Bolinder J, Kager L, Ostman J, Arner P: Differences at the receptor and 
postreceptor levels between human omental and subcutaneous adipose tissue 
in the action of insulin on lipolysis. Diabetes 32:117-123, 1983 
71.  Zierath JR, Livingston JN, Thorne A, Bolinder J, Reynisdottir S, Lonnqvist F, 
Arner P: Regional difference in insulin inhibition of non-esterified fatty acid 
release from human adipocytes: relation to insulin receptor phosphorylation 
and intracellular signalling through the insulin receptor substrate-1 pathway. 
Diabetologia 41:1343-1354, 1998 
72.  Wueest S, Yang X, Liu J, Schoenle EJ, Konrad D: Inverse regulation of basal 
lipolysis in perigonadal and mesenteric fat depots in mice. Am J Physiol 
Endocrinol Metab 302:E153-160, 2012 
 74
73.  Tchkonia T, Giorgadze N, Pirtskhalava T, Thomou T, DePonte M, Koo A, 
Forse RA, Chinnappan D, Martin-Ruiz C, von Zglinicki T, Kirkland JL: Fat 
depot-specific characteristics are retained in strains derived from single human 
preadipocytes. Diabetes 55:2571-2578, 2006 
74.  Satoor SN, Puranik AS, Kumar S, Williams MD, Ghale M, Rahalkar A, 
Karandikar MS, Shouche Y, Patole M, Bhonde R, Yajnik CS, Hardikar AA: 
Location, location, location: Beneficial effects of autologous fat transplantation. 
Sci Rep 1:81, 2011 
75.  Rytka JM, Wueest S, Schoenle EJ, Konrad D: The portal theory supported by 
venous drainage-selective fat transplantation. Diabetes 60:56-63, 2011 
76.  Konrad D, Rudich A, Schoenle EJ: Improved glucose tolerance in mice 
receiving intraperitoneal transplantation of normal fat tissue. Diabetologia 
50:833-839, 2007 
77.  Macotela Y, Emanuelli B, Mori MA, Gesta S, Schulz TJ, Tseng YH, Kahn CR: 
Intrinsic differences in adipocyte precursor cells from different white fat depots. 
Diabetes 61:1691-1699, 2012 
78.  Tchkonia T, Lenburg M, Thomou T, Giorgadze N, Frampton G, Pirtskhalava T, 
Cartwright A, Cartwright M, Flanagan J, Karagiannides I, Gerry N, Forse RA, 
Tchoukalova Y, Jensen MD, Pothoulakis C, Kirkland JL: Identification of depot-
specific human fat cell progenitors through distinct expression profiles and 
developmental gene patterns. Am J Physiol Endocrinol Metab 292:E298-307, 
2007 
79.  Dahlman I, Elsen M, Tennagels N, Korn M, Brockmann B, Sell H, Eckel J, 
Arner P: Functional annotation of the human fat cell secretome. Arch Physiol 
Biochem 118:84-91, 2012 
80.  Hocking SL, Wu LE, Guilhaus M, Chisholm DJ, James DE: Intrinsic depot-
specific differences in the secretome of adipose tissue, preadipocytes, and 
adipose tissue-derived microvascular endothelial cells. Diabetes 59:3008-3016, 
2010 
81.  Pardo M, Roca-Rivada A, Seoane LM, Casanueva FF: Obesidomics: 
contribution of adipose tissue secretome analysis to obesity research. 
Endocrine 41:374-383, 2012 
82.  Peinado JR, Pardo M, de la Rosa O, Malagon MM: Proteomic characterization 
of adipose tissue constituents, a necessary step for understanding adipose 
tissue complexity. Proteomics 12:607-620, 2012 
83.  Caesar R, Manieri M, Kelder T, Boekschoten M, Evelo C, Muller M, Kooistra T, 
Cinti S, Kleemann R, Drevon CA: A combined transcriptomics and lipidomics 
analysis of subcutaneous, epididymal and mesenteric adipose tissue reveals 
marked functional differences. PLoS One 5:e11525, 2010 
84.  Jove M, Moreno-Navarrete JM, Pamplona R, Ricart W, Portero-Otin M, 
Fernandez-Real JM: Human omental and subcutaneous adipose tissue exhibit 
specific lipidomic signatures. FASEB J 28:1071-1081, 2014 
85.  Rehrer CW, Karimpour-Fard A, Hernandez TL, Law CK, Stob NR, Hunter LE, 
Eckel RH: Regional differences in subcutaneous adipose tissue gene 
expression. Obesity (Silver Spring) 20:2168-2173, 2012 
86.  Sackmann-Sala L, Berryman DE, Munn RD, Lubbers ER, Kopchick JJ: 
Heterogeneity among white adipose tissue depots in male C57BL/6J mice. 
Obesity (Silver Spring) 20:101-111, 2012 
87.  Wronska A, Kmiec Z: Structural and biochemical characteristics of various 
white adipose tissue depots. Acta Physiol (Oxf) 205:194-208, 2012 
 75
88.  Young SG, Zechner R: Biochemistry and pathophysiology of intravascular and 
intracellular lipolysis. Genes Dev 27:459-484, 2013 
89.  Black PN, DiRusso CC: Transmembrane movement of exogenous long-chain 
fatty acids: proteins, enzymes, and vectorial esterification. Microbiol Mol Biol 
Rev 67:454-472, table of contents, 2003 
90.  Glatz JF, Luiken JJ, Bonen A: Membrane fatty acid transporters as regulators 
of lipid metabolism: implications for metabolic disease. Physiol Rev 90:367-
417, 2010 
91.  Anderson CM, Stahl A: SLC27 fatty acid transport proteins. Mol Aspects Med 
34:516-528, 2013 
92.  Furuhashi M, Hotamisligil GS: Fatty acid-binding proteins: role in metabolic 
diseases and potential as drug targets. Nat Rev Drug Discov 7:489-503, 2008 
93.  Coleman RA, Mashek DG: Mammalian triacylglycerol metabolism: synthesis, 
lipolysis, and signaling. Chem Rev 111:6359-6386, 2011 
94.  Haemmerle G, Zimmermann R, Hayn M, Theussl C, Waeg G, Wagner E, 
Sattler W, Magin TM, Wagner EF, Zechner R: Hormone-sensitive lipase 
deficiency in mice causes diglyceride accumulation in adipose tissue, muscle, 
and testis. J Biol Chem 277:4806-4815, 2002 
95.  Karlsson M, Contreras JA, Hellman U, Tornqvist H, Holm C: cDNA cloning, 
tissue distribution, and identification of the catalytic triad of monoglyceride 
lipase. Evolutionary relationship to esterases, lysophospholipases, and 
haloperoxidases. J Biol Chem 272:27218-27223, 1997 
96.  Zimmermann R, Strauss JG, Haemmerle G, Schoiswohl G, Birner-
Gruenberger R, Riederer M, Lass A, Neuberger G, Eisenhaber F, Hermetter A, 
Zechner R: Fat mobilization in adipose tissue is promoted by adipose 
triglyceride lipase. Science 306:1383-1386, 2004 
97.  Jenkins CM, Mancuso DJ, Yan W, Sims HF, Gibson B, Gross RW: 
Identification, cloning, expression, and purification of three novel human 
calcium-independent phospholipase A2 family members possessing 
triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem 
279:48968-48975, 2004 
98.  Villena JA, Roy S, Sarkadi-Nagy E, Kim KH, Sul HS: Desnutrin, an adipocyte 
gene encoding a novel patatin domain-containing protein, is induced by fasting 
and glucocorticoids: ectopic expression of desnutrin increases triglyceride 
hydrolysis. J Biol Chem 279:47066-47075, 2004 
99.  Yeaman SJ: Hormone-sensitive lipase--new roles for an old enzyme. Biochem 
J 379:11-22, 2004 
100.  Schwenk RW, Holloway GP, Luiken JJ, Bonen A, Glatz JF: Fatty acid 
transport across the cell membrane: regulation by fatty acid transporters. 
Prostaglandins Leukot Essent Fatty Acids 82:149-154, 2010 
101.  Jump DB: N-3 polyunsaturated fatty acid regulation of hepatic gene 
transcription. Curr Opin Lipidol 19:242-247, 2008 
102.  Schmitz G, Ecker J: The opposing effects of n-3 and n-6 fatty acids. Prog Lipid 
Res 47:147-155, 2008 
103. MacDougald OA, Burant CF: The rapidly expanding family of adipokines. Cell 
Metab 6:159-161, 2007 
104.  Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional 
cloning of the mouse obese gene and its human homologue. Nature 372:425-
432, 1994 
 76
105.  Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P: Recombinant mouse OB 
protein: evidence for a peripheral signal linking adiposity and central neural 
networks. Science 269:546-549, 1995 
106.  Flier JS: Obesity wars: molecular progress confronts an expanding epidemic. 
Cell 116:337-350, 2004 
107.  Wiest R, Moleda L, Farkas S, Scherer M, Kopp A, Wonckhaus U, Buchler C, 
Scholmerich J, Schaffler A: Splanchnic concentrations and postprandial 
release of visceral adipokines. Metabolism 59:664-670, 2010 
108.  Morton GJ, Schwartz MW: Leptin and the central nervous system control of 
glucose metabolism. Physiol Rev 91:389-411, 2011 
109.  Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier 
JS: Role of leptin in the neuroendocrine response to fasting. Nature 382:250-
252, 1996 
110.  Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS: The role of falling 
leptin levels in the neuroendocrine and metabolic adaptation to short-term 
starvation in healthy men. J Clin Invest 111:1409-1421, 2003 
111.  Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI: Leptin 
modulates the T-cell immune response and reverses starvation-induced 
immunosuppression. Nature 394:897-901, 1998 
112.  Lee MJ, Fried SK: Integration of hormonal and nutrient signals that regulate 
leptin synthesis and secretion. Am J Physiol Endocrinol Metab 296:E1230-
1238, 2009 
113.  Pan H, Guo J, Su Z: Advances in understanding the interrelations between 
leptin resistance and obesity. Physiol Behav 130C:157-169, 2014 
114.  Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards 
GJ, Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriarty A, Moore KJ, 
Smutko JS, Mays GG, Wool EA, Monroe CA, Tepper RI: Identification and 
expression cloning of a leptin receptor, OB-R. Cell 83:1263-1271, 1995 
115.  Hoggard N, Mercer JG, Rayner DV, Moar K, Trayhurn P, Williams LM: 
Localization of leptin receptor mRNA splice variants in murine peripheral 
tissues by RT-PCR and in situ hybridization. Biochem Biophys Res Commun 
232:383-387, 1997 
116.  Lollmann B, Gruninger S, Stricker-Krongrad A, Chiesi M: Detection and 
quantification of the leptin receptor splice variants Ob-Ra, b, and, e in different 
mouse tissues. Biochem Biophys Res Commun 238:648-652, 1997 
117.  Cheung CC, Clifton DK, Steiner RA: Proopiomelanocortin neurons are direct 
targets for leptin in the hypothalamus. Endocrinology 138:4489-4492, 1997 
118.  Muoio DM, Dohm GL, Fiedorek FT, Jr., Tapscott EB, Coleman RA: Leptin 
directly alters lipid partitioning in skeletal muscle. Diabetes 46:1360-1363, 1997 
119.  Unger RH, Zhou YT, Orci L: Regulation of fatty acid homeostasis in cells: novel 
role of leptin. Proc Natl Acad Sci U S A 96:2327-2332, 1999 
120.  Wang MY, Lee Y, Unger RH: Novel form of lipolysis induced by leptin. J Biol 
Chem 274:17541-17544, 1999 
121.  Shimabukuro M, Koyama K, Chen G, Wang MY, Trieu F, Lee Y, Newgard CB, 
Unger RH: Direct antidiabetic effect of leptin through triglyceride depletion of 
tissues. Proc Natl Acad Sci U S A 94:4637-4641, 1997 
122.  Fried SK, Ricci MR, Russell CD, Laferrere B: Regulation of leptin production in 
humans. J Nutr 130:3127S-3131S, 2000 
123.  Steinberg GR, Watt MJ, Fam BC, Proietto J, Andrikopoulos S, Allen AM, 
Febbraio MA, Kemp BE: Ciliary neurotrophic factor suppresses hypothalamic 
 77
AMP-kinase signaling in leptin-resistant obese mice. Endocrinology 147:3906-
3914, 2006 
124.  Steinberg GR, Parolin ML, Heigenhauser GJ, Dyck DJ: Leptin increases FA 
oxidation in lean but not obese human skeletal muscle: evidence of peripheral 
leptin resistance. Am J Physiol Endocrinol Metab 283:E187-192, 2002 
125.  Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum 
protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 
270:26746-26749, 1995 
126.  Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adipose-specific gene 
dysregulated in obesity. J Biol Chem 271:10697-10703, 1996 
127.  Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, 
Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa 
Y: Novel modulator for endothelial adhesion molecules: adipocyte-derived 
plasma protein adiponectin. Circulation 100:2473-2476, 1999 
128.  Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, 
Matsuzawa Y: Circulating concentrations of the adipocyte protein adiponectin 
are decreased in parallel with reduced insulin sensitivity during the progression 
to type 2 diabetes in rhesus monkeys. Diabetes 50:1126-1133, 2001 
129.  Galic S, Oakhill JS, Steinberg GR: Adipose tissue as an endocrine organ. Mol 
Cell Endocrinol 316:129-139, 2010 
130.  Trujillo ME, Scherer PE: Adipose tissue-derived factors: impact on health and 
disease. Endocr Rev 27:762-778, 2006 
131.  Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu 
M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, 
Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, 
Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, 
Kadowaki T: Targeted disruption of AdipoR1 and AdipoR2 causes abrogation 
of adiponectin binding and metabolic actions. Nat Med 13:332-339, 2007 
132.  Halberg N, Schraw TD, Wang ZV, Kim JY, Yi J, Hamilton MP, Luby-Phelps K, 
Scherer PE: Systemic fate of the adipocyte-derived factor adiponectin. 
Diabetes 58:1961-1970, 2009 
133.  Schraw T, Wang ZV, Halberg N, Hawkins M, Scherer PE: Plasma adiponectin 
complexes have distinct biochemical characteristics. Endocrinology 149:2270-
2282, 2008 
134.  Scherer PE: Adipose tissue: from lipid storage compartment to endocrine 
organ. Diabetes 55:1537-1545, 2006 
135.  Wijesekara N, Krishnamurthy M, Bhattacharjee A, Suhail A, Sweeney G, 
Wheeler MB: Adiponectin-induced ERK and Akt phosphorylation protects 
against pancreatic beta cell apoptosis and increases insulin gene expression 
and secretion. J Biol Chem 285:33623-33631, 2010 
136.  Brown JE, Conner AC, Digby JE, Ward KL, Ramanjaneya M, Randeva HS, 
Dunmore SJ: Regulation of beta-cell viability and gene expression by distinct 
agonist fragments of adiponectin. Peptides 31:944-949, 2010 
137.  Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman 
BT, Halberg N, Rutkowski JM, Wade MR, Tenorio VM, Kuo MS, Brozinick JT, 
Zhang BB, Birnbaum MJ, Summers SA, Scherer PE: Receptor-mediated 
activation of ceramidase activity initiates the pleiotropic actions of adiponectin. 
Nat Med 17:55-63, 2011 
138.  Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc C, Itani SI, Lodish HF, 
Ruderman NB: Enhanced muscle fat oxidation and glucose transport by 
ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-
 78
activated protein kinase activation. Proc Natl Acad Sci U S A 99:16309-16313, 
2002 
139.  Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, 
Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, 
Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates 
glucose utilization and fatty-acid oxidation by activating AMP-activated protein 
kinase. Nat Med 8:1288-1295, 2002 
140.  Turer AT, Scherer PE: Adiponectin: mechanistic insights and clinical 
implications. Diabetologia 55:2319-2326, 2012 
141.  Berg AH, Combs TP, Du X, Brownlee M, Scherer PE: The adipocyte-secreted 
protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953, 2001 
142.  Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, 
Schraw T, Durand JL, Li H, Li G, Jelicks LA, Mehler MF, Hui DY, Deshaies Y, 
Shulman GI, Schwartz GJ, Scherer PE: Obesity-associated improvements in 
metabolic profile through expansion of adipose tissue. J Clin Invest 117:2621-
2637, 2007 
143.  Asterholm IW, Scherer PE: Enhanced metabolic flexibility associated with 
elevated adiponectin levels. Am J Pathol 176:1364-1376, 2010 
144.  Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, 
Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y: Adiponectin, a new 
member of the family of soluble defense collagens, negatively regulates the 
growth of myelomonocytic progenitors and the functions of macrophages. 
Blood 96:1723-1732, 2000 
145.  Ohashi K, Parker JL, Ouchi N, Higuchi A, Vita JA, Gokce N, Pedersen AA, 
Kalthoff C, Tullin S, Sams A, Summer R, Walsh K: Adiponectin promotes 
macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 
285:6153-6160, 2010 
146.  Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H: Adiponectin induces the anti-
inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem 
Biophys Res Commun 323:630-635, 2004 
147.  Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, 
Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB: Retinol-binding 
protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J 
Med 354:2552-2563, 2006 
148.  McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, 
Crocker J, Barnett AH, Kumar S: Increased resistin gene and protein 
expression in human abdominal adipose tissue. J Clin Endocrinol Metab 
87:2407, 2002 
149.  Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, 
O'Rahilly S: Resistin / Fizz3 expression in relation to obesity and peroxisome 
proliferator-activated receptor-gamma action in humans. Diabetes 50:2199-
2202, 2001 
150.  Nagaev I, Smith U: Insulin resistance and type 2 diabetes are not related to 
resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res 
Commun 285:561-564, 2001 
151.  Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, 
Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S: 
Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic 
NAD biosynthetic enzyme. Cell Metab 6:363-375, 2007 
152.  Harwood HJ, Jr.: The adipocyte as an endocrine organ in the regulation of 
metabolic homeostasis. Neuropharmacology 63:57-75, 2012 
 79
153.  Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS: The fatty 
acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and 
inflammatory activity. Macrophage expression of aP2 impacts peroxisome 
proliferator-activated receptor gamma and IkappaB kinase activities. J Biol 
Chem 280:12888-12895, 2005 
154.  Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, 
Sham PC, Lam KS: Circulating adipocyte-fatty acid binding protein levels 
predict the development of the metabolic syndrome: a 5-year prospective study. 
Circulation 115:1537-1543, 2007 
155.  Catalan V, Gomez-Ambrosi J, Rodriguez A, Salvador J, Fruhbeck G: 
Adipokines in the treatment of diabetes mellitus and obesity. Expert Opin 
Pharmacother 10:239-254, 2009 
156.  Maury E, Brichard SM: Adipokine dysregulation, adipose tissue inflammation 
and metabolic syndrome. Mol Cell Endocrinol 314:1-16, 2010 
157.  Pickup JC, Crook MA: Is type II diabetes mellitus a disease of the innate 
immune system? Diabetologia 41:1241-1248, 1998 
158.  Hotamisligil GS: Inflammation and metabolic disorders. Nature 444:860-867, 
2006 
159.  Olefsky JM, Glass CK: Macrophages, inflammation, and insulin resistance. 
Annu Rev Physiol 72:219-246, 2010 
160.  Gregor MF, Hotamisligil GS: Inflammatory mechanisms in obesity. Annu Rev 
Immunol 29:415-445, 2011 
161.  Tateya S, Kim F, Tamori Y: Recent advances in obesity-induced inflammation 
and insulin resistance. Front Endocrinol (Lausanne) 4:93, 2013 
162.  Winer S, Winer DA: The adaptive immune system as a fundamental regulator 
of adipose tissue inflammation and insulin resistance. Immunol Cell Biol 
90:755-762, 2012 
163.  Sell H, Habich C, Eckel J: Adaptive immunity in obesity and insulin resistance. 
Nat Rev Endocrinol 8:709-716, 2012 
164.  Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor 
necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 
259:87-91, 1993 
165.  Kriegler M, Perez C, DeFay K, Albert I, Lu SD: A novel form of TNF/cachectin 
is a cell surface cytotoxic transmembrane protein: ramifications for the complex 
physiology of TNF. Cell 53:45-53, 1988 
166.  Ruan H, Lodish HF: Insulin resistance in adipose tissue: direct and indirect 
effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 14:447-455, 
2003 
167.  Ranjit S, Boutet E, Gandhi P, Prot M, Tamori Y, Chawla A, Greenberg AS, Puri 
V, Czech MP: Regulation of fat specific protein 27 by isoproterenol and TNF-
alpha to control lipolysis in murine adipocytes. J Lipid Res 52:221-236, 2011 
168.  Hotamisligil GS: Mechanisms of TNF-alpha-induced insulin resistance. Exp 
Clin Endocrinol Diabetes 107:119-125, 1999 
169.  Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE: Local 
and systemic insulin resistance resulting from hepatic activation of IKK-beta 
and NF-kappaB. Nat Med 11:183-190, 2005 
170.  Stephens JM, Lee J, Pilch PF: Tumor necrosis factor-alpha-induced insulin 
resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor 
substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated 
signal transduction. J Biol Chem 272:971-976, 1997 
 80
171.  Moller DE: Potential role of TNF-alpha in the pathogenesis of insulin resistance 
and type 2 diabetes. Trends Endocrinol Metab 11:212-217, 2000 
172.  Trujillo ME, Lee MJ, Sullivan S, Feng J, Schneider SH, Greenberg AS, Fried 
SK: Tumor necrosis factor alpha and glucocorticoid synergistically increase 
leptin production in human adipose tissue: role for p38 mitogen-activated 
protein kinase. J Clin Endocrinol Metab 91:1484-1490, 2006 
173.  Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS: Protection from 
obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 
389:610-614, 1997 
174.  Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: 
IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-
alpha- and obesity-induced insulin resistance. Science 271:665-668, 1996 
175.  Steinberg GR, McAinch AJ, Chen MB, O'Brien PE, Dixon JB, Cameron-Smith 
D, Kemp BE: The suppressor of cytokine signaling 3 inhibits leptin activation of 
AMP-kinase in cultured skeletal muscle of obese humans. J Clin Endocrinol 
Metab 91:3592-3597, 2006 
176.  Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HF: Tumor necrosis 
factor-alpha suppresses adipocyte-specific genes and activates expression of 
preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by 
TNF-alpha is obligatory. Diabetes 51:1319-1336, 2002 
177.  Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, 
Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW, Shulman GI: 
Mechanism by which fatty acids inhibit insulin activation of insulin receptor 
substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. 
J Biol Chem 277:50230-50236, 2002 
178.  Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R: Effects of an engineered 
human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic 
control in patients with NIDDM. Diabetes 45:881-885, 1996 
179.  Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA: Effects of 
infliximab treatment on insulin resistance in patients with rheumatoid arthritis 
and ankylosing spondylitis. Ann Rheum Dis 64:765-766, 2005 
180.  Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, 
Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A, et al.: Complementary 
DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to 
produce immunoglobulin. Nature 324:73-76, 1986 
181.  Jin X, Zimmers TA, Perez EA, Pierce RH, Zhang Z, Koniaris LG: Paradoxical 
effects of short- and long-term interleukin-6 exposure on liver injury and repair. 
Hepatology 43:474-484, 2006 
182.  Pedersen BK, Febbraio MA: Point: Interleukin-6 does have a beneficial role in 
insulin sensitivity and glucose homeostasis. J Appl Physiol 102:814-816, 2007 
183.  Mooney RA: Counterpoint: Interleukin-6 does not have a beneficial role in 
insulin sensitivity and glucose homeostasis. J Appl Physiol 102:816-818; 
discussion 818-819, 2007 
184.  Spangenburg EE: Point:counterpoint: Interleukin-6 does/does not have a 
beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 
102:820; author reply 825, 2007 
185.  Fischer CP: Interleukin-6 in acute exercise and training: what is the biological 
relevance? Exerc Immunol Rev 12:6-33, 2006 
186.  Allen TL, Febbraio MA: IL6 as a mediator of insulin resistance: fat or fiction? 
Diabetologia 53:399-402, 2010 
 81
187.  Benito M: Tissue specificity on insulin action and resistance: past to recent 
mechanisms. Acta Physiol (Oxf) 201:297-312, 2011 
188.  Kraakman MJ, Allen TL, Whitham M, Iliades P, Kammoun HL, Estevez E, 
Lancaster GI, Febbraio MA: Targeting gp130 to prevent inflammation and 
promote insulin action. Diabetes Obes Metab 15 Suppl 3:170-175, 2013 
189.  Gadient RA, Otten UH: Interleukin-6 (IL-6)--a molecule with both beneficial and 
destructive potentials. Prog Neurobiol 52:379-390, 1997 
190.  Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, 
Coppack SW: Subcutaneous adipose tissue releases interleukin-6, but not 
tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196-4200, 
1997 
191.  Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue tumor 
necrosis factor and interleukin-6 expression in human obesity and insulin 
resistance. Am J Physiol Endocrinol Metab 280:E745-751, 2001 
192.  Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE: 
Circulating interleukin-6 in relation to adiposity, insulin action, and insulin 
secretion. Obes Res 9:414-417, 2001 
193.  Weigert C, Hennige AM, Lehmann R, Brodbeck K, Baumgartner F, Schauble M, 
Haring HU, Schleicher ED: Direct cross-talk of interleukin-6 and insulin signal 
transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol 
Chem 281:7060-7067, 2006 
194.  Rotter V, Nagaev I, Smith U: Interleukin-6 (IL-6) induces insulin resistance in 
3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, 
overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 
278:45777-45784, 2003 
195.  Rieusset J, Bouzakri K, Chevillotte E, Ricard N, Jacquet D, Bastard JP, Laville 
M, Vidal H: Suppressor of cytokine signaling 3 expression and insulin 
resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 
53:2232-2241, 2004 
196.  Feve B, Bastard JP: The role of interleukins in insulin resistance and type 2 
diabetes mellitus. Nat Rev Endocrinol 5:305-311, 2009 
197.  van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, 
Hiscock N, Moller K, Saltin B, Febbraio MA, Pedersen BK: Interleukin-6 
stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 
88:3005-3010, 2003 
198.  Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R: 
Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-
L1 adipocytes. Biochem Biophys Res Commun 301:1045-1050, 2003 
199.  Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D: 
Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo 
and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. 
Cancer Res 52:4113-4116, 1992 
200.  Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K, 
Taga T, Kishimoto T: IL-6-induced homodimerization of gp130 and associated 
activation of a tyrosine kinase. Science 260:1808-1810, 1993 
201.  Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, 
Kishimoto T: Interleukin-6 triggers the association of its receptor with a possible 
signal transducer, gp130. Cell 58:573-581, 1989 
202.  Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, 
Ohlsson C, Jansson JO: Interleukin-6-deficient mice develop mature-onset 
obesity. Nat Med 8:75-79, 2002 
 82
203.  Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA: Lipid and 
carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: 
absence of development of age-related obesity. Am J Physiol Endocrinol 
Metab 287:E182-187, 2004 
204.  Matthews VB, Allen TL, Risis S, Chan MH, Henstridge DC, Watson N, Zaffino 
LA, Babb JR, Boon J, Meikle PJ, Jowett JB, Watt MJ, Jansson JO, Bruce CR, 
Febbraio MA: Interleukin-6-deficient mice develop hepatic inflammation and 
systemic insulin resistance. Diabetologia 53:2431-2441, 2010 
205.  Wunderlich FT, Strohle P, Konner AC, Gruber S, Tovar S, Bronneke HS, Juntti-
Berggren L, Li LS, van Rooijen N, Libert C, Berggren PO, Bruning JC: 
Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic 
inflammation and improves systemic insulin action. Cell Metab 12:237-249, 
2010 
206.  Nye C, Kim J, Kalhan SC, Hanson RW: Reassessing triglyceride synthesis in 
adipose tissue. Trends Endocrinol Metab 19:356-361, 2008 
207.  Czech MP, Tencerova M, Pedersen DJ, Aouadi M: Insulin signalling 
mechanisms for triacylglycerol storage. Diabetologia 56:949-964, 2013 
208.  Samuel VT, Shulman GI: Mechanisms for insulin resistance: common threads 
and missing links. Cell 148:852-871, 2012 
209.  Wueest S, Rapold RA, Schumann DM, Rytka JM, Schildknecht A, Nov O, 
Chervonsky AV, Rudich A, Schoenle EJ, Donath MY, Konrad D: Deletion of 
Fas in adipocytes relieves adipose tissue inflammation and hepatic 
manifestations of obesity in mice. J Clin Invest 120:191-202, 2010 
210.  Clegg DJ, Gotoh K, Kemp C, Wortman MD, Benoit SC, Brown LM, D'Alessio D, 
Tso P, Seeley RJ, Woods SC: Consumption of a high-fat diet induces central 
insulin resistance independent of adiposity. Physiol Behav 103:10-16, 2011 
211.  Benani A, Hryhorczuk C, Gouaze A, Fioramonti X, Brenachot X, Guissard C, 
Krezymon A, Duparc T, Colom A, Nedelec E, Rigault C, Lemoine A, Gascuel J, 
Gerardy-Schahn R, Valet P, Knauf C, Lorsignol A, Penicaud L: Food intake 
adaptation to dietary fat involves PSA-dependent rewiring of the arcuate 
melanocortin system in mice. J Neurosci 32:11970-11979, 2012 
212.  Pendergast JS, Branecky KL, Yang W, Ellacott KLJ, Niswender KD, Yamazaki 
S: High-fat diet acutely affects circadian organisation and eating behavior. 
European Journal of Neuroscience 37:1350-1356, 2013 
213.  Scherer T, Lindtner C, Zielinski E, O'Hare J, Filatova N, Buettner C: Short term 
voluntary overfeeding disrupts brain insulin control of adipose tissue lipolysis. J 
Biol Chem 287:33061-33069, 2012 
214.  Turner N, Kowalski GM, Leslie SJ, Risis S, Yang C, Lee-Young RS, Babb JR, 
Meikle PJ, Lancaster GI, Henstridge DC, White PJ, Kraegen EW, Marette A, 
Cooney GJ, Febbraio MA, Bruce CR: Distinct patterns of tissue-specific lipid 
accumulation during the induction of insulin resistance in mice by high-fat 
feeding. Diabetologia 56:1638-1648, 2013 
215.  Voigt A, Agnew K, van Schothorst EM, Keijer J, Klaus S: Short-term, high fat 
feeding-induced changes in white adipose tissue gene expression are highly 
predictive for long-term changes. Mol Nutr Food Res 57:1423-1434, 2013 
216.  Montgomery MK, Hallahan NL, Brown SH, Liu M, Mitchell TW, Cooney GJ, 
Turner N: Mouse strain-dependent variation in obesity and glucose 
homeostasis in response to high-fat feeding. Diabetologia 56:1129-1139, 2013 
217.  Koza RA, Nikonova L, Hogan J, Rim JS, Mendoza T, Faulk C, Skaf J, Kozak 
LP: Changes in gene expression foreshadow diet-induced obesity in genetically 
identical mice. PLoS Genet 2:e81, 2006 
 83
218.  Lee RK, Hittel DS, Nyamandi VZ, Kang L, Soh J, Sensen CW, Shearer J: 
Unconventional microarray design reveals the response to obesity is largely 
tissue specific: analysis of common and divergent responses to diet-induced 
obesity in insulin-sensitive tissues. Appl Physiol Nutr Metab 37:257-268, 2012 
219.  Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ, Storlien LH: 
Development of muscle insulin resistance after liver insulin resistance in high-
fat-fed rats. Diabetes 40:1397-1403, 1991 
220.  Elgazar-Carmon V, Rudich A, Hadad N, Levy R: Neutrophils transiently 
infiltrate intra-abdominal fat early in the course of high-fat feeding. J Lipid Res 
49:1894-1903, 2008 
221.  Chalkley SM, Hettiarachchi M, Chisholm DJ, Kraegen EW: Five-hour fatty acid 
elevation increases muscle lipids and impairs glycogen synthesis in the rat. 
Metabolism 47:1121-1126, 1998 
222.  Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, 
Kraegen EW, White MF, Shulman GI: Free fatty acid-induced insulin resistance 
is associated with activation of protein kinase C theta and alterations in the 
insulin signaling cascade. Diabetes 48:1270-1274, 1999 
223.  Ramirez I, Friedman MI: Dietary Hyperphagia in Rats - Role of Fat, 
Carbohydrate, and Energy Content. Physiology & Behavior 47:1157-1163, 
1990 
224.  Melhorn SJ, Krause EG, Scott KA, Mooney MR, Johnson JD, Woods SC, Sakai 
RR: Acute exposure to a high-fat diet alters meal patterns and body 
composition. Physiol Behav 99:33-39, 2010 
225.  Saltiel AR: Insulin resistance in the defense against obesity. Cell Metab 
15:798-804, 2012 
226.  Gauthier MS, Favier R, Lavoie JM: Time course of the development of non-
alcoholic hepatic steatosis in response to high-fat diet-induced obesity in rats. 
Br J Nutr 95:273-281, 2006 
227.  Foster MT, Shi H, Seeley RJ, Woods SC: Removal of intra-abdominal visceral 
adipose tissue improves glucose tolerance in rats: role of hepatic triglyceride 
storage. Physiol Behav 104:845-854, 2011 
228.  Foster MT, Shi H, Softic S, Kohli R, Seeley RJ, Woods SC: Transplantation of 
non-visceral fat to the visceral cavity improves glucose tolerance in mice: 
investigation of hepatic lipids and insulin sensitivity. Diabetologia 54:2890-2899, 
2011 
229.  Bahr J, Kloting N, Kloting I, Follak N: Transplantation of adipose tissue protects 
BB/OK rats from type 1 diabetes development. Transpl Immunol 24:238-240, 
2011 
230.  Barrera C, Gatica A, Morgan C: Obese visceral adipose tissue grafted in lean 
mice can alter glucose homeostasis and energy efficiency. J Biol Regul 
Homeost Agents 26:411-417, 2012 
231.  Nov O, Shapiro H, Ovadia H, Tarnovscki T, Dvir I, Shemesh E, Kovsan J, 
Shelef I, Carmi Y, Voronov E, Apte RN, Lewis E, Haim Y, Konrad D, Bashan N, 
Rudich A: Interleukin-1beta regulates fat-liver crosstalk in obesity by auto-
paracrine modulation of adipose tissue inflammation and expandability. PLoS 
One 8:e53626, 2013 
232.  Zhao J, Yi C, Li L, Zheng Y, Wu K, Liang L, Xia W, Guo S: Observations on the 
survival and neovascularization of fat grafts interchanged between C57BL/6-
gfp and C57BL/6 mice. Plast Reconstr Surg 130:398e-406e, 2012 
 84
233.  Zimmerman HA, Olson KC, Chen G, Lynch CJ: Adipose transplant for inborn 
errors of branched chain amino acid metabolism in mice. Mol Genet Metab 
109:345-353, 2013 
234.  Mauer MM, Harris RB, Bartness TJ: The regulation of total body fat: lessons 
learned from lipectomy studies. Neurosci Biobehav Rev 25:15-28, 2001 
235.  Trayhurn P: White adipose tissue grafts--keeping in contact. Am J Physiol 
Regul Integr Comp Physiol 289:R297-R298, 2005 
236. Lacy EL, Bartness TJ: Effects of white adipose tissue grafts on total body fat 
and cellularity are dependent on graft type and location. Am J Physiol Regul 
Integr Comp Physiol 289:R380-R388, 2005 
237.  Shi H, Bartness TJ: White adipose tissue sensory nerve denervation mimics 
lipectomy-induced compensatory increases in adiposity. Am J Physiol Regul 
Integr Comp Physiol 289:R514-R520, 2005 
238.  Gunawardana SC, Piston DW: Reversal of type 1 diabetes in mice by brown 
adipose tissue transplant. Diabetes 61:674-682, 2012 
239.  Trojahn Kolle SF, Oliveri RS, Glovinski PV, Elberg JJ, Fischer-Nielsen A, 
Drzewiecki KT: Importance of mesenchymal stem cells in autologous fat 
grafting: a systematic review of existing studies. J Plast Surg Hand Surg 46:59-
68, 2012 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 85
8. Acknowledgements 
 
First and foremost I would like to thank my supervisor Prof. Dr. med. Daniel Konrad, 
PhD, for having given me the opportunity to carry out these research projects in his 
laboratory. For his patience, perseverance on ideas and especially his humanity in 
harder times during the past 3.5 years. Furthermore I have to thank Dr. Stephan 
Wüest and Dr. Flurin Item for helpful discussion, friendliness and conversations 
about and beyond science. 
 
I would also like to thank Prof. Dr. Marc Donath, Prof. Dr. Carsten Wagner, and Prof. 
Dr. Thomas Lutz for having taken the responsibility of forming my PhD committee 
and their valuable input during meetings. 
 
A great thank goes to my colleagues Annie (Siew Hung) Chin and Fabrizio Lucchini 
for fruitful discussions and a cosy laboratory atmosphere. 
 
I would like to express my gratitude further to my other laboratory colleagues from the 
C Lab for helpful technical and scientific advice, and discussions beyond our four 
walls, especially to Maren Dietrich, Dr. Richard Züllig and Dr. Markus Niessen and 
the Krützfeldt group with Amir Mizbani, Katarina Turcekova, Artur Galimov, Tatiane 
Gorski, and Angelika Hartung. 
 
A special thank goes to the laboratory technicians Heidi, Diri, Claudia, Cornelia, and 
to the secretary Michèle for keeping things running and their friendly and patient 
behaviour with us PhD-students. 
 
I am indebted to Mirzet Delic for helpful discussions all beyond science during the 
past 1.5 years! 
 
And last but not least to my family, my mum and beloved dad. 
 
 86
